Document:

Loan and Security Agreement

 Exhibit 10.19 
 LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY
AGREEMENT (this “Agreement”) dated as of July 15, 2011 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street,
Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, the “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its
capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and PROTOX THERAPEUTICS INC., a corporation amalgamated under the Business Corporations Act (British Columbia), with offices located at
1500 – 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3E8 (“Parent”) and PROTOX THERAPEUTICS CORP., a Delaware corporation, with offices located at 1258 Prospect Street, La Jolla, California, 92037
(“Protox US” and, collectively with Parent, “Borrowers” and, each individually, a “Borrower”), provides the terms on which the Lenders shall lend to Borrowers and Borrowers shall repay the Lenders.
The parties agree as follows: 
  

	1.	 ACCOUNTING AND OTHER TERMS 

 1.1 Accounting terms not defined in this Agreement shall be construed in accordance with GAAP. Calculations and determinations must be made in accordance with GAAP. Capitalized terms not otherwise
defined in this Agreement shall have the meanings set forth in Section 14. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. All
references to “Dollars” or “$” are United States Dollars, unless otherwise noted. 
  

	2.	 LOANS AND TERMS OF PAYMENT 

 2.1 Promise to Pay. Borrowers hereby unconditionally promise to pay each Lender, the outstanding principal amount of all Term Loans advanced to Borrowers, or any of them, by such Lender and accrued
and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement. 
 2.2 Term Loans. 
 (a) Availability. Subject to the
terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make one (1) term loan to Parent on the Effective Date in an aggregate amount of Fifteen Million Dollars ($15,000,000) according to each Lender’s Term
Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a “Term Loan,” and collectively as the “Term Loans”). After repayment, no Term Loan may be
re-borrowed. 
 (b) Repayment. Borrowers shall make monthly payments of interest
only commencing on the first (1st) Payment Date
following the Funding Date of the Term Loans, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Commencing on the Amortization Date, and
continuing on the Payment Date of each month thereafter, Borrowers shall make consecutive equal monthly payments of principal and interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct
absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to thirty (30) months. All unpaid
principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on the Maturity Date. The Term Loans may only be prepaid in accordance with Sections 2.2(c) and 2.2(d). 

(c) Mandatory Prepayments. If the Term Loans are accelerated following the occurrence of an Event of Default,
Borrowers shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through
the prepayment date, (ii) the Final Payment, (iii) the Prepayment Fee, plus (iv) all other sums, that shall have become due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due
amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of 

  
 1 

 
the Term Loans in full, Borrowers shall pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect of the Term Loan(s).

 (d) Permitted Prepayment of Term Loans. Borrowers shall have the option to prepay all, but not less
than all, of the Term Loans advanced by the Lenders under this Agreement, provided Parent (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least fifteen (15) days prior to such prepayment, and
(ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid
interest thereon through the prepayment date, (B) the Final Payment, (C) the Prepayment Fee, plus (D) all other sums, that shall have become due and payable hereunder, including Lenders’ Expenses, if any, and interest at the
Default Rate with respect to any past due amounts. 
 2.3 Payment of Interest on the Credit Extensions.

 (a) Interest Rate. Subject to Section 2.3(b), the principal amount outstanding under the Term
Loans shall accrue interest at a fixed per annum rate (which rate shall be fixed for the duration of the applicable Term Loan) equal to the Basic Rate, determined by Collateral Agent on the Funding Date of the applicable Term Loan, which interest
shall be payable monthly in accordance with Sections 2.2(b) and 2.3(e). Interest shall accrue on each Term Loan commencing on, and including, the day on which the Term Loan is made, and shall accrue on a Term Loan, or any outstanding portion
thereof, for the day on which the Term Loan or such outstanding portion is paid. 
 (b) Default Rate.
Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall bear interest at a rate per annum which is five percentage points (5.00%) above the rate that is otherwise applicable thereto (the
“Default Rate”). Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise
prejudice or limit any rights or remedies of Collateral Agent. 
 (c) 360-Day Year. Interest shall be
computed on the basis of a 360-day year consisting of twelve (12) months of thirty (30) days. 
 (d)
Debit of Accounts. Collateral Agent and each Lender may debit any of Borrowers’ deposit accounts, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrowers owe the Lenders under the Loan
Documents when due. These debits shall not constitute a set-off. 
 (e) Payments. Except as otherwise
expressly provided herein, all loan payments by Borrowers hereunder shall be made to the respective Lender to which such payments are owed, at such Lender’s office in immediately available funds on the date specified herein. Unless otherwise
provided, interest is payable monthly on the Payment Date of each month. Payments of principal and/or interest received after 12:00 noon Eastern time are considered received at the opening of business on the next Business Day. When a payment is due
on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrowers hereunder or under any other Loan Document,
including payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United
States and in immediately available funds. 
 2.4 Secured Promissory Notes. Each Term Loan shall be
evidenced by a Secured Promissory Note in the form attached as Exhibit D hereto (each a “Secured Promissory Note”), and shall be repayable as set forth herein. Each Borrower irrevocably authorizes each Lender to make
or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record
reflecting the making of such Term Loan or (as the case may be) the receipt of such payment. The outstanding amount of each Term Loan set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal
amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrowers

  
 2 

 
hereunder or under any Secured Promissory Note to make payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as to
the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrowers shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor. 

2.5 Fees. Borrowers shall pay to Collateral Agent: 

(a) Facility Fee. A fully earned, non-refundable facility fee of One Hundred Fifty Thousand Dollars ($150,000) to
be shared between the Lenders pursuant to their respective Commitment Percentages, receipt of which hereby is acknowledged; 
 (b) Final Payment. The Final Payment, when due hereunder, for the sole account of Oxford; 
 (c) Prepayment Fee. The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares; and 

(d) Lenders’ Expenses. All Lenders’ Expenses (including reasonable attorneys’ fees and expenses for
documentation and negotiation of this Agreement) incurred through and after the Effective Date, when due. 

2.6 Withholding Taxes. Payments received by Lenders from any Borrower hereunder will be made free and clear of any
withholding taxes. Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires any Borrower to make any such withholding or deduction from any such payment or other sum payable
hereunder to Lenders, each Borrower hereby covenants and agrees that the amount due from Borrowers with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of such
required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding or deduction been required and Borrowers shall pay the full amount withheld or deducted to the relevant Governmental
Authority. Borrowers will, upon request, furnish Lenders with proof reasonably satisfactory to Lenders indicating that each Borrower has made such withholding payment provided, however, that Borrowers need not make any withholding payment if the
amount or validity of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrowers. The agreements and obligations of Borrowers contained in this
Section 2.6 shall survive the termination of this Agreement. 
  

	3.	 CONDITIONS OF LOANS 

 3.1 Conditions Precedent to Initial Credit Extension. Each Lender’s obligation to make a Term Loan is subject to the condition precedent that Collateral Agent shall consent to or shall have
received, in form and substance satisfactory to Collateral Agent, such documents, and completion of such other matters, as Collateral Agent may reasonably deem necessary or appropriate, including, without limitation: 

(a) duly executed original signatures to the Loan Documents to which each Borrower is a party; 

(b) duly executed original signatures to Control Agreements, or similar, with respect to each of Borrowers’ deposit
and securities accounts, as applicable; 
 (c) duly executed original Secured Promissory Notes in favor of each
Lender according to its Commitment Percentage; 
 (d) the certificate(s) for the Shares, together with
assignment(s) separate from certificate, duly executed in blank; 

  
 3 

 (e) the Operating Documents of Parent and a good standing certificate of
Parent certified by the Registrar of Companies of the Province of British Columbia and each other jurisdiction in which Parent is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date;

 (f) the Operating Documents of Protox US and good standing certificates of Protox US certified by the
Secretary of State of the State of Delaware, California and each state in which Protox US is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date; 

(g) the Perfection Certificate for each Borrower; 

(h) duly executed original signatures to an officer’s certificate for each Borrower, in a form acceptable to
Collateral Agent; 
 (i) Collateral Agent shall have received certified copies, dated as of a recent date, of
financing statement searches, as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statement searches either constitute Permitted Liens or have
been or, in connection with the initial Credit Extension, will be terminated or released; 
 (j) a
landlord’s consent executed in favor of Collateral Agent in respect of each Borrower’s leased location(s); 
 (k) a legal opinion of Borrowers’ counsel dated as of the Effective Date together with the duly executed original signatures thereto; 

(l) duly executed original signatures to the Investment Letter; 

(m) evidence satisfactory to Collateral Agent that the insurance policies required by Section 6.5 hereof are in full
force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Lenders; and 

(n) payment of the fees and Lenders’ Expenses then due as specified in Section 2.5 hereof. 

3.2 Conditions Precedent to all Credit Extensions. The obligation of each Lender to make each Credit Extension,
including the initial Credit Extension, is subject to the following conditions precedent: 
 (a) receipt by
Collateral Agent of an executed Payment/Advance Form in the form of Exhibit B attached hereto; 

(b) the representations and warranties in Section 5 hereof shall be true, in all material respects on the date of
the Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the
text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be
continuing or result from the Credit Extension. Each Credit Extension is each Borrower’s representation and warranty on that date that the representations and warranties in Section 5 hereof are true, accurate and complete in all material
respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations
and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; 
 (c) in such Lender’s sole discretion, there has not been any Material Adverse Change or any material adverse deviation by Borrowers from the most recent business plan of Borrowers presented to and
accepted by Collateral Agent; and 
 (d) payment of the fees and Lenders’ Expenses then due as specified in
Section 2.5 hereof. 

  
 4 

 3.3 Covenant to Deliver. Each Borrower agrees to deliver to
Collateral Agent each item required to be delivered to Collateral Agent under this Agreement as a condition precedent to any Credit Extension. Each Borrower expressly agrees that a Credit Extension made prior to the receipt by Collateral Agent of
any such item shall not constitute a waiver by the Lenders of each Borrower’s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in each Lender’s sole discretion. 

3.4 Procedures for Borrowing. Subject to the prior satisfaction of all other applicable conditions to the making
of a Term Loan set forth in this Agreement, on the Funding Date, each Lender shall credit and/or transfer (as applicable) to the Designated Deposit Account, an amount equal to its Term Loan Commitment. 

 

	4.	 CREATION OF SECURITY INTEREST 

4.1 Grant of Security Interest. Each Borrower hereby grants Collateral Agent, for the ratable benefit of the
Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or
hereafter acquired or arising, and all proceeds and products thereof. Each Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest
in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to have priority to Collateral Agent’s Lien. If a Borrower shall acquire a commercial tort claim (as defined in the Code), Parent shall
promptly notify Collateral Agent in a writing signed by Parent and the relevant Borrower, of the general details thereof (and further details as may be required by Collateral Agent) and grant to Collateral Agent, for the ratable benefit of the
Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent. 

If this Agreement is terminated, Collateral Agent’s Lien in the Collateral shall continue until the Obligations
(other than inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders’ obligation to make Credit Extensions has
terminated, Collateral Agent shall, at Borrowers’ sole cost and expense, release its Liens in the Collateral and all rights therein shall revert to Borrowers. 

4.2 Authorization to File Financing Statements. Each Borrower hereby authorizes Collateral Agent to file financing
statements or take any other action required to perfect Collateral Agent’s security interests in the Collateral, without notice to any Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s and each
Lender’s interest or rights hereunder, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by either Borrower or any other Person, shall be deemed to violate the rights of
Collateral Agent and Lenders under the Code. Such financing statements may indicate the Collateral as “all assets of the Debtor or words of similar effect, or as being of an equal or lesser scope, or with greater detail, all in Collateral
Agent’s discretion. 
 4.3 Pledge of Collateral. Each Borrower hereby pledges, assigns and grants to
Collateral Agent, for the ratable benefit of the Lenders, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities
declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations. On the Effective Date, or, to the extent not certificated as of the Effective Date, within ten
(10) days of the certification of any Shares, the certificate or certificates for the Shares will be delivered to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by the relevant Borrower. To the extent
required by the terms and conditions governing the Shares, Borrowers shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares. Upon the occurrence of an Event of Default
hereunder, Collateral Agent and/or any Lender may effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and/or such Lender and cause new (as applicable)
certificates representing such securities to be issued in the name of Collateral Agent and/or such Lender or their transferee. Each Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may
reasonably request to perfect or continue the perfection of Collateral Agent’s security interest in the Shares. Unless an Event of Default shall have occurred and be continuing, Borrowers shall be entitled to exercise any voting rights with
respect to the Shares and to give 

  
 5 

 
consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would be inconsistent with any of the
terms of this Agreement or which would constitute or create any violation of any of such terms. All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default.

  

	5.	 REPRESENTATIONS AND WARRANTIES 

Each Borrower represents and warrants to Collateral Agent and the Lenders as follows at all times: 

5.1 Due Organization, Authorization: Power and Authority. Borrower and each of its Subsidiaries is duly existing
and Borrower is in good standing as a Registered Organization in its jurisdiction of organization and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of
its business or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower’s business. In connection with this Agreement, Borrower has
delivered to Collateral Agent a completed perfection certificate signed by an officer of Borrower (the “Perfection Certificate”). Borrower represents and warrants that (a) Borrower’s exact legal name is that indicated on
the Perfection Certificate and on the signature page hereof; (b) Borrower is an organization of the type and is organized in the jurisdiction set forth in the Perfection Certificate; (c) the Perfection Certificate accurately sets forth
Borrower’s organizational identification number or accurately states that Borrower has none; (d) the Perfection Certificate accurately sets forth Borrower’s place of business, or, if more than one, its chief executive office as well
as Borrower’s mailing address (if different than its chief executive office); (e) Borrower (and each of its predecessors) has not, in the past five (5) years, changed its jurisdiction of organization, organizational structure or type,
or any organizational number assigned by its jurisdiction; and (f) all other information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is accurate and complete (it being understood and agreed that
Borrower may from time to time update certain information in the Perfection Certificate (including the information set forth in clause (d) above) after the Effective Date to the extent permitted by one or more specific provisions in this
Agreement). If Borrower or any Subsidiary is not now a Registered Organization but later becomes one, Borrower shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person’s organizational identification number
within five (5) Business Days of receiving such organizational identification number. 
 The execution,
delivery and performance by Borrower of the Loan Documents to which it is a party have been duly authorized, and do not (i) conflict with any of Borrower’s organizational documents, including the Operating Documents, (ii) contravene,
conflict with, constitute a default under or violate any material Requirement of Law, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which
Borrower or any of its Subsidiaries or any of its property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such
Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b), or (v) constitute an event of default under any material agreement by which Borrower or any of its
Subsidiaries or its properties is bound. Borrower is not in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a material adverse effect on
Borrower’s business. 
 5.2 Collateral. 

(a) Borrower has good title to, has rights in, and the power to transfer each item of the Collateral upon which it
purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and Borrower does not have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the
Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificate delivered to Collateral Agent in connection herewith with respect of which Borrower has given Collateral Agent notice and taken such actions as are
necessary to give Collateral Agent a perfected security interest therein. The Accounts are bona fide, existing obligations of the Account Debtors. 
 (b) On the Effective Date, the Collateral is not in the possession of any third party bailee (such as a warehouse) except as disclosed in the Perfection Certificate or as permitted pursuant to
Section 7.2, and, as of the Effective Date, no such third party bailee possesses components of the Collateral in excess of Fifty 

  
 6 

 
Thousand Dollars ($50,000). None of the components of the Collateral shall be maintained at locations other than as disclosed in the Perfection Certificate on the Effective Date or as permitted
pursuant to Section 7.2. In the event that Borrower, after the Effective Date, intends to store or otherwise deliver any portion of the Collateral to a bailee in excess of Fifty Thousand Dollars ($50,000), then Borrower will first receive the
written consent of Collateral Agent and such bailee must execute and deliver a bailee agreement in form and substance reasonably satisfactory to Collateral Agent. 

(c) All Inventory is in all material respects of good and marketable quality, free from material defects. 

(d) Borrower is the sole owner of the Intellectual Property it purports to own, except for (i) non-exclusive
licenses granted to its customers in the ordinary course of business and licenses for the use of the Intellectual Property of Borrower or its Subsidiaries that are approved by Borrower’s Board of Directors and which could not result in a legal
transfer of title of the licensed property but that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discrete geographical areas outside of the United States, (ii) over-the-counter software
that is commercially available to the public, and (iii) material Intellectual Property licensed to Borrower and noted on the Perfection Certificate. To the best of Borrower’s knowledge (i) each of Borrower’s patents is valid and
enforceable and no part of Borrower’s Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (ii) no claim has been made that any part of the Intellectual Property or any practice by Borrower violates the
rights of any third party except to the extent such claim could not reasonably be expected to have a material adverse effect on Borrower’s business. Except as noted on the Perfection Certificate, Borrower is not a party to, nor is bound by, any
material license or other agreement with respect to which Borrower is the licensee that (i) prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other
property, or (ii) for which a default under or termination of which could interfere with Collateral Agent’s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent within ten (10) days of entering into
or becoming bound by any license or agreement (other than over-the-counter software that is commercially available to the public). Borrower shall take such commercially reasonable steps as Collateral Agent requests to obtain the consent of, or
waiver by, any Person whose consent or waiver is necessary for (i) all licenses or agreements to be deemed “Collateral” and for Collateral Agent to have a security interest in it that might otherwise be restricted or prohibited by law
or by the terms of any such license or agreement, whether now existing or entered into in the future, and (ii) Collateral Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with
Collateral Agent’s rights and remedies under this Agreement and the other Loan Documents. Without limiting the foregoing, Borrower shall, within one hundred eighty (180) days of the Effective Date, take such commercially reasonable steps
to obtain the consent of, or waiver by, the licensors under the licenses identified on Annex I (attached to Exhibit A hereto) for such licenses to be deemed “Collateral” and for Collateral Agent to have a security interest therein. For
greater certainty, failure of Borrower to obtain the consent or waiver described in the immediately preceding sentences, after taking such commercially reasonable steps, shall not constitute an Event of Default. 

5.3 Litigation. Except as disclosed on the Perfection Certificate, there are no actions, suits, investigations, or
proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than One Hundred Thousand Dollars ($100,000.00). 

5.4 No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements
for Borrower and its Subsidiaries delivered to Collateral Agent fairly present, in all material respects the consolidated financial condition of Borrower and its Subsidiaries and the consolidated results of operations of Borrower and its
Subsidiaries. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender. 

5.5 Solvency. The fair salable value of Borrower’s assets (including goodwill minus disposition costs)
exceeds the fair value of its liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower is able to pay its debts (including trade debts) as they mature. 

5.6 Regulatory Compliance. Borrower is not an “investment company” or a company “controlled”
by an “investment company” under the Investment Company Act of 1940, as amended. Borrower is not engaged as 

  
 7 

 
one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower has complied in all material respects with
the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company” as
each term is defined and used in the Public Utility Holding Company Act of 2005. Borrower has not violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a material adverse effect on its business. None of
Borrower’s or any of its Subsidiaries’ properties or assets has been used by Borrower or any Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous
substance other than in material compliance with applicable laws. Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental
Authorities that are necessary to continue their respective businesses as currently conducted except where failure to obtain or make such consents, declarations, filings or notices could not reasonably be expected to have a Material Adverse Change.

 Neither Borrower or its Affiliates or any of their respective agents acting or benefiting in any capacity in
connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or
attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. Neither Borrower, nor, to the knowledge of Borrower, any of its Affiliates or agents acting or benefiting in any capacity in
connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or
otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. 

5.7 Subsidiaries; Investments. Borrower does not own any stock, shares, partnership interests or other equity
securities except for Permitted Investments. 
 5.8 Tax Returns and Payments; Pension Contributions.
Borrower and its Subsidiaries have timely filed or have timely obtained extensions for filing all required tax returns and reports, and Borrower and its Subsidiaries have timely paid all foreign, federal, state, provincial and local taxes,
assessments, deposits and contributions owed by Borrower and its Subsidiaries in all jurisdictions in which Borrower or its Subsidiaries are subject to taxes, including the United States, unless such taxes are being contested in accordance with the
following sentence. Borrower and its Subsidiaries may defer payment of any contested taxes, provided that Borrower or such Subsidiary (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently
instituted and conducted, (b) notifies Collateral Agent in writing of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the governmental authority
levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a “Permitted Lien”. Borrower is unaware of any claims or adjustments proposed for any of Borrower or its Subsidiaries prior tax years which
could result in additional taxes becoming due and payable by Borrower or its Subsidiaries. Borrower and its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with
their terms, and Borrower and its Subsidiaries have not withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably
be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

5.9 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely as working capital and to
fund its general business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. 
 5.10 Shares. Borrower has full power and authority to create a first lien on the Shares and no disability or contractual obligation exists that would prohibit Borrower from pledging the Shares
pursuant to this Agreement. To Borrower’s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares. The Shares have been and will
be duly authorized and validly issued, and are fully paid and non-assessable. To Borrower’s knowledge, the Shares are not the subject of 

  
 8 

 
any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of no reasonable grounds for the institution of any such proceedings. 

5.11 Full Disclosure. No written representation, warranty or other statement of Borrower in any certificate or
written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Collateral Agent or any Lender,
contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized that the projections and forecasts provided by
Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results). 

5.12 Definition of “Knowledge.” For purposes of the Loan Documents, whenever a representation or
warranty is made to Borrower’s knowledge or awareness, to the “best of” Borrower’s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of the Responsible
Officers. 
  

	6.	 AFFIRMATIVE COVENANTS 

 Except as otherwise indicated, each Borrower shall, and shall cause each of its Subsidiaries to, do all of the following: 

6.1 Government Compliance. 

(a) Maintain its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of
organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a material adverse effect on Borrower’s business or operations. Borrower shall comply, and have each Subsidiary
comply, with all laws, ordinances and regulations to which it is subject, the noncompliance with which could reasonably be expected to have a material adverse effect on Borrower’s business. 

(b) Obtain and keep in full force and effect, all of the Governmental Approvals necessary for the performance by Borrower
of its obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Lenders, in all of the Collateral. Borrower shall promptly provide copies to Collateral Agent of any material
Governmental Approvals obtained by Borrower. 
 6.2 Financial Statements, Reports, Certificates. Parent
shall 
 (a) Deliver to each Lender: (i) as soon as available, but no later than thirty (30) days
after the last day of each month, a company prepared consolidated and consolidating balance sheet, income statement and cash flow statement covering the consolidated operations of Parent and its Subsidiaries for such month certified by a Responsible
Officer and in a form reasonably acceptable to Collateral Agent; (ii) as soon as available, but no later than one hundred twenty (120) days after the last day of Parent’s fiscal year, audited consolidated financial statements prepared
under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent certified public accounting firm or chartered accountant firm acceptable to Collateral Agent in its reasonable discretion
(provided that any of Deloitte, PricewaterhouseCoopers, Ernst & Young and KPMG is acceptable to Collateral Agent); (iii) as soon as available after approval thereof by Parent’s Board of Directors, but no later than thirty
(30) days after the last day of each of Parent’s fiscal years, Borrowers’ financial projections for the entire current fiscal year as approved by Parent’s Board of Directors, which such annual projections shall be set forth in a
month-by-month format (such annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the “Annual Projections”); (iv) within five (5) days of delivery, copies of all
statements, reports and notices made available to any Borrower’s security holders or holders of Subordinated Debt; (v) (x) in the event that any Borrower becomes subject to the reporting requirements under the Securities Exchange Act
of 1934, as amended, within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission, and (y) within five (5) days of filing, all reports filed with and/or mandated by the
Toronto Stock Exchange; (vi) within thirty (30) days after the end of each calendar quarter, 

  
 9 

 
notice of (A) any material change in the composition of the Intellectual Property, (B) notice of the registration of any copyright, including any subsequent ownership right of any
Borrower in or to any copyright, patent or trademark, and (C) prompt notice of any Borrower’s knowledge of any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property; (vii) as
soon as available, but no later than thirty (30) days after the last day of each month, copies of the month-end account statements for each deposit account or securities account maintained by each Borrower and any Subsidiary, which statements
may be provided to Collateral Agent by Parent or directly from the applicable institution(s), and (viii) other financial information as reasonably requested by Collateral Agent or any Lender. Documents required to be delivered pursuant to the
terms hereof (to the extent any such documents are included in materials otherwise filed with a securities exchange, including the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which
Borrower posts such documents, or provides a link thereto, on Borrower’s website on the internet at Borrower’s website address. 
 (b) Concurrently with the delivery of the financial statements specified in Section 6.2(a)(i) above but no later than thirty (30) days after the last day of each month, deliver to each Lender, a
duly completed Compliance Certificate signed by a Responsible Officer. 
 (c) Keep proper books of record and
account in accordance with GAAP in all material respects, in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities. Each Borrower shall allow, at the sole cost of Borrowers,
Collateral Agent and Lenders, during regular business hours upon reasonable prior notice (except while an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any
of its books and records, and to conduct a collateral audit and analysis of its operations and the Collateral. Such audits shall be conducted no more often than twice every year unless (and more frequently if) an Event of Default has occurred and is
continuing. 
 6.3 Inventory; Returns. Keep all Inventory in good and marketable condition, free from
material defects. Returns and allowances between Borrower and its Account Debtors shall follow Borrower’s customary practices as they exist at the Effective Date. Borrower must promptly notify Collateral Agent of all returns, recoveries,
disputes and claims that involve more than One Hundred Thousand Dollars ($100,000) individually or in the aggregate in any calendar year. 
 6.4 Taxes; Pensions. Timely file and require each of its Subsidiaries to timely file, all required tax returns and reports or extensions therefor and timely pay, and require each of its
Subsidiaries to timely file, all foreign, federal, state, provincial and local taxes, assessments, deposits and contributions owed by Borrower and its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of
Section 5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their
terms. 
 6.5 Insurance. Keep its business and the Collateral insured for risks and in amounts standard
for companies in Borrower’s industry and location and as Collateral Agent may reasonably request. Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent. All property policies
shall have a lender’s loss payable endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as an additional
insured. All policies (or the loss payable and additional insured endorsements) shall provide that the insurer shall endeavor to give Collateral Agent at least thirty (30) days notice before canceling, amending, or declining to renew its
policy. At Collateral Agent’s request, Borrower shall deliver certified copies of policies and evidence of all premium payments. Proceeds payable under any policy shall, at Collateral Agent’s option, be payable to Collateral Agent on
behalf of the Lenders on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to $50,000
with respect to any loss, but not exceeding $100,000, in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired
property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and
during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the 

  
 10 

 
ratable benefit of the Lenders, on account of the Obligations. If Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of
payment to third persons and Collateral Agent, Collateral Agent may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral Agent deems prudent.

 6.6 Operating Accounts. 

(a) Maintain all of Borrower’s and its Subsidiaries’ operating and other deposit accounts and securities
accounts with RBC, with respect to Parent, and First Republic Bank, with respect to Protox US, in each case in accounts which are subject to a Control Agreement in favor of Collateral Agent, as applicable. 

(b) Borrower and its Subsidiaries shall provide Collateral Agent five (5) days’ prior written notice before
establishing any Collateral Account at or with any Person other than RBC (with respect to any Collateral Account in Canada), or First Republic Bank. In addition, for each Collateral Account that Borrower or any of its Subsidiaries at any time
maintains, Borrower shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to
perfect Collateral Agent’s Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated without prior written consent of Collateral Agent . The provisions of the previous sentence shall
not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s or such Subsidiary’s employees and identified to Collateral Agent by Borrower as
such. Collateral Agent agrees not to place a “hold” or deliver a notice of exclusive control, entitlement order, or other similar directions or instructions under any Control Agreement or similar agreements providing control of any
Collateral unless an Event of Default has occurred. 
 (c) Borrower and its Subsidiaries shall not maintain any
Collateral Accounts except Collateral Accounts located in the United States or Canada in accordance with Sections 6.6(a) and (b). 
 6.7 New Equity. Parent shall receive, net cash proceeds from the sale and issuance of Parent’s equity securities after the Effective Date, of no less than (i) Seven Million Five Hundred
Thousand Canadian dollars ($7,500,000 Cdn) by December 31, 2011; and (ii) an additional Seven Million Five Hundred Thousand Canadian dollars ($7,500,000 Cdn) by March 31, 2012. 

6.8 Protection of Intellectual Property Rights. Borrower shall: (a) protect, defend and maintain the validity
and enforceability of its Intellectual Property that is material to Borrower’s business; (b) promptly advise Collateral Agent in writing upon becoming aware of material infringement by a third party of its Intellectual Property; and
(c) not allow any Intellectual Property material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Collateral Agent’s written consent. If Borrower (i) obtains any patent, registered trademark or
servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then
Borrower shall provide written notice thereof to Collateral Agent and each Lender within thirty (30) days after the end of each calendar quarter and shall execute such intellectual property security agreements and other documents and take such
other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent in such property. If Borrower decides to register any
copyrights or mask works in the United States Copyright Office and/or the Canadian Intellectual Property Office, Borrower shall: (x) provide Collateral Agent and each Lender with at least fifteen (15) days prior written notice of
Borrower’s intent to register such copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office and/or the Canadian Intellectual Property Office (excluding exhibits thereto);
(y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected
security interest in favor of Collateral Agent in the copyrights or mask works intended to be registered with the United States Copyright Office and/or the Canadian Intellectual Property Office; and (z) record such intellectual property
security agreement with the United States Copyright Office and/or the Canadian Intellectual Property Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office and/or the Canadian
Intellectual Property Office. Upon recordation, Borrower shall promptly provide to Collateral Agent with evidence of the recording of the 

  
 11 

 
intellectual property security agreement necessary for Collateral Agent to perfect and maintain a first priority perfected security interest in such property. 

6.9 Litigation Cooperation. From the date hereof and continuing through the termination of this Agreement, make
available to Collateral Agent, without expense to Collateral Agent or the Lenders, Borrower and its officers, employees and agents and Borrower’s Books, to the extent that Collateral Agent may reasonably deem them necessary to prosecute or
defend any third-party suit or proceeding instituted by or against Collateral Agent or the Lenders with respect to any Collateral or relating to Borrower. 
 6.10 Notices of Litigation and Default. Borrower will give prompt written notice to Collateral Agent of any litigation or governmental proceedings pending or threatened (in writing) against
Borrower or any of its Subsidiaries which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of One Hundred Thousand Dollars ($100,000) or more or which could reasonably be expected to have a material
adverse effect with respect to Borrower’s business. Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in any event within three (3) Business Days) upon Borrower becoming aware of the
existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Collateral Agent of such occurrence, which such notice shall include
a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default. 

6.11 Investments in Subsidiaries. Borrower shall not, and shall not permit any Subsidiary to, contribute, assign
or otherwise transfer assets to any Subsidiary or Subsidiaries, other than Permitted Investments. 
 6.12
Creation/Acquisition of Subsidiaries. In the event Borrower or any Subsidiary creates or acquires any Subsidiary, Borrower and such Subsidiary shall promptly notify Collateral Agent of the creation or acquisition of such new Subsidiary and take
all such action as may be reasonably required by Collateral Agent to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and
security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto); and Borrower shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security interest
in the Shares of each Subsidiary; provided that a Borrower shall not be required to pledge more than sixty-five percent (65%) of the Shares of any Subsidiary of such Borrower not incorporated or organized under the laws of one of the States or
jurisdictions of the United States, and any such Subsidiary shall not be required to execute a guaranty in favor of Collateral Agent or become a co-Borrower hereunder, if such Borrower demonstrates to Collateral Agent’s reasonable satisfaction
that a pledge of more than sixty five percent (65%) of the Shares, or a guaranty from such Subsidiary, or the adding of such Subsidiary as a co-Borrower hereunder, creates a present and existing adverse tax consequence to such Borrower under
the U.S. Internal Revenue Code. 
 6.13 Borrower’s Books. Parent shall, within one hundred eighty
(180) days of the Effective Date, cause all Borrower’s Books to be relocated and at all times thereafter maintained at the premises occupied by Protox US (provided such location is subject, or at such other location as shall be subject, to
a landlord waiver (or similar) in form and content reasonably acceptable to Collateral Agent). 
 6.14
Further Assurances. 
 (a) Execute any further instruments and take further action as Collateral Agent
reasonably requests to perfect or continue Collateral Agent’s Lien in the Collateral or to effect the purposes of this Agreement. 
 (b) Deliver to Collateral Agent, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority
that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to Borrower’s business or otherwise on the operations of Borrower or any of its Subsidiaries. 

  
 12 

	7.	 NEGATIVE COVENANTS 

 No Borrower shall, nor shall any Borrower permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders: 

7.1 Dispositions. Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively,
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn-out or obsolete Equipment;
(c) in connection with Permitted Liens and Permitted Investments; (d) of non-exclusive licenses for the use of the Intellectual Property of Borrower or its Subsidiaries in the ordinary course of business; (e) of licenses for the use
of the Intellectual Property of Borrower or its Subsidiaries that are approved by Borrower’s Board of Directors and which could not result in a legal transfer of title of the licensed property but that may be exclusive in respects other than
territory and that may be exclusive as to territory only as to discrete geographical areas outside of the United States; (f) made from one Borrower to another Borrower; or (g) made from a Borrower to a Subsidiary that is a co-Borrower or
guarantor of the Obligations or Transfers made from a Subsidiary or guarantor of the Obligations to a Borrower. 

7.2 Changes in Business, Management, Ownership, or Business Locations. (a) Engage in or permit any of its
Subsidiaries to engage in any business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto; (b) liquidate or dissolve; or (c) (i) permit any Key Person to cease to be actively
engaged in the management of Borrower unless a replacement for such Key Person is approved by Borrower’s Board of Directors and engaged by Borrower within ninety (90) days of such Key Person’s departure or other cessation of activity,
or (ii) enter into any transaction or series of related transactions in which the shareholders or stockholders of Borrower who were not shareholders or stockholders immediately prior to the first such transaction own more than forty-nine
percent (49%) of the voting shares or stock of Borrower immediately after giving effect to such transaction or related series of such transactions (other than by the sale of Borrower’s equity securities in a public offering, in a private
placement of public equity or to venture capital investors so long as Borrower identifies to Collateral Agent the venture capital investors prior to the closing of the transaction). Borrower shall not, without at least thirty (30) days prior
written notice to Collateral Agent: (A) add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Fifty Thousand Dollars ($50,000) in Borrower’s assets or property),
(B) change its jurisdiction of organization, (C) change its organizational structure or type, (D) change its legal name, or (E) change any organizational number (if any) assigned by its jurisdiction of organization. Collateral
Agent agrees not to deliver a notice to a bailee purporting to exercise dominion or control over any Collateral or any other similar direction or instruction under any bailee agreement with a Borrower unless an Event of Default has occurred.

 7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or
consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person. A Subsidiary may merge or consolidate into another Subsidiary
(provided such surviving Subsidiary is a “co-Borrower” hereunder or has provided a secured guaranty of Borrower’s Obligations hereunder) or into Borrower provided Borrower is the surviving legal entity, and as long as no Event of
Default is occurring prior thereto or arises as a result therefrom. 
 7.4 Indebtedness. Create, incur,
assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness. 
 7.5 Encumbrance. Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its
Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens that are permitted by the terms of this Agreement to have priority over
Collateral Agent’s Lien), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent or any Lender) with any Person which directly or indirectly prohibits or has the effect of prohibiting
Borrower or any Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower’s or any Subsidiary’s Intellectual Property, except as is otherwise permitted in Section 7.1
hereof and the definition of “Permitted Liens” herein. 

  
 13 

 7.6 Maintenance of Collateral Accounts. Maintain any Collateral
Account except pursuant to the terms of Section 6.6 hereof. 
 7.7 Distributions; Investments.
(a) Pay any dividends (other than dividends payable solely in shares of capital stock of Borrower) or make any distribution or payment or redeem, retire or purchase any securities or capital stock of Borrower (other than repurchases pursuant to
the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases do not exceed Fifty Thousand Dollars ($50,000) in the
aggregate per fiscal year) or (b) directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so. Notwithstanding the foregoing, Subsidiaries of the Borrowers shall be permitted to pay
dividends, or make distributions, to the Borrowers. 
 7.8 Transactions with Affiliates. Directly or
indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for (a) transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable
to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person or (b) transactions otherwise permitted pursuant to the terms of Section 7 hereof. 

7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt, except under the terms of the
subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof except in accordance with
the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject or adversely affect the subordination thereof to Obligations owed to the Lenders. 

7.10 Compliance. Become an “investment company” or a company controlled by an “investment
company”, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve
System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair
Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a material adverse effect on Borrower’s business, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to
withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result
in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 
 7.11 Compliance with Anti-Terrorism Laws. Collateral Agent hereby notifies Borrower that pursuant to the requirements of Anti-Terrorism Laws, and Collateral Agent’s policies and practices,
Collateral Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and its principals, which information includes the name and address of Borrower and its principals and such other information
that will allow Collateral Agent to identify such party in accordance with Anti-Terrorism Laws. Borrower will not, nor will Borrower permit any Subsidiary or Affiliate to, directly or indirectly, knowingly enter into any documents, instruments,
agreements or contracts with any Person listed on the OFAC Lists. Borrower shall immediately notify Collateral Agent if Borrower has knowledge that Borrower or any Subsidiary or Affiliate is listed on the OFAC Lists or (a) is convicted on,
(b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. Borrower will not, nor will Borrower permit any Subsidiary or
Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the
benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law, or
(iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.

  
 14 

	8.	 EVENTS OF DEFAULT 

 Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement: 

8.1 Payment Default. Borrowers fail to (a) make any payment of principal or interest on any Credit Extension
on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of
acceleration pursuant to Section 9.1 (a) hereof). During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period); 

8.2 Covenant Default. 
 (a) Borrowers fail or neglect to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (New Equity), 6.8
(Protection of Intellectual Property Rights), 6.9 (Litigation Cooperation), 6.10 (Notices of Default), 6.11 (Investments in Subsidiaries) or 6.12 (Creation/Acquisition of Subsidiaries) or any Borrower violates any covenant in Section 7; or

 (b) Borrowers or any of their Subsidiaries fails or neglects to perform, keep, or observe any other term,
provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be
cured, has failed to cure the default within ten (10) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrowers be
cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrowers shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default,
and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Grace periods provided under this Section shall not apply, among other
things, to financial covenants or any other covenants set forth in subsection (a) above; 
 8.3 Material
Adverse Change. A Material Adverse Change occurs; provided that, termination of that certain Patent License Agreement dated July 18, 2006, as amended effective July 24, 2008, with respect to license L-112-2006/0, and that certain
Patent License Agreement dated July 24, 2008, with respect to license L-127- 2008/0, both between Parent and certain agencies of the United States Public Health Service within the Department of Health and Human Services, shall not, in and of
itself, constitute a Material Adverse Change for purposes of this Section 8.3; 
 8.4 Attachment; Levy;
Restraint on Business. 
 (a) (i) The service of process seeking to attach, by trustee or similar process,
any funds of a Borrower or of any entity under control of a Borrower (including a Subsidiary) on deposit with any Lender or any Lender’s Affiliate or any bank or other institution at which a Borrower maintains a Collateral Account, or
(ii) a notice of lien, levy, or assessment is filed against any of a Borrower’s assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof,
discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; and 

(b) (i) any material portion of a Borrower’s assets is attached, seized, levied on, or comes into possession of a
trustee or receiver, or (ii) any court order enjoins, restrains, or prevents a Borrower from conducting any part of its business; 
 8.5 Insolvency (a) any Borrower is unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b) any Borrower begins an Insolvency Proceeding; or
(c) an Insolvency Proceeding is begun against any Borrower and not dismissed or stayed within thirty (30) days (but no Credit 

  
 15 

 
Extensions shall be made while any of the conditions described in clause (a) exist and/or until any Insolvency Proceeding is dismissed); 

8.6 Other Agreements. There is a default in any agreement to which a Borrower is a party with a third party or
parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of One Hundred Thousand Dollars ($100,000) or that could have a material adverse effect on a
Borrower’s business; provided, however, that the Event of Default under this Section 8.6 caused by the occurrence of a default with respect to such agreement shall be cured or waived for purposes of this Agreement upon Collateral Agent
receiving written notice from the party asserting such default of the cure or waiver of such default, if at the time of such cure or waiver (i) neither Collateral Agent nor any Lender has declared an Event of Default under this Agreement and/or
exercised any rights with respect thereto; (ii) any such cure or waiver does not result in an Event of Default under any other provision of this Agreement or any Loan Document; and (iii) in connection with any such cure or waiver, the
terms of any agreement with such third party are not modified or amended in any manner which could in the good faith judgment of Collateral Agent or the Lenders be materially less advantageous to Borrowers. 

8.7 Judgments. One or more judgments, orders, or decrees for the payment of money in an amount, individually or in
the aggregate, of at least Fifty Thousand Dollars ($50,000) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against a Borrower and shall remain unsatisfied,
unvacated, or unstayed for a period of ten (10) days after the entry thereof (provided that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or decree); 

8.8 Misrepresentations. Any Borrower or any Person acting for any Borrower makes any representation, warranty, or
other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or to induce Collateral Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation,
warranty, or other statement is incorrect in any material respect when made; 
 8.9 Subordinated Debt. A
default or breach occurs under any subordination, intercreditor or other similar agreement between a Borrower and any creditor of a Borrower that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders,
or any creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any terms of such agreement; or 
 8.10 Governmental Approvals. Any Governmental Approval shall have been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the ordinary course for a full term or
(b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions
described in clause (a) above, and as to (a) or (b) such decision or such revocation, rescission, suspension, modification or non-renewal (i) has, or could reasonably be expected to have, a Material Adverse Change, or
(ii) adversely affects the legal qualifications of a Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably
be expected to affect the status of or legal qualifications of a Borrower or any of its Subsidiaries to hold any Governmental Approval in any other jurisdiction that could reasonably be expected to have a material adverse effect on such
Borrower’s business. 
 8.11 Lien Priority. Any Lien created hereunder or by any other Loan Document
shall at any time fail to constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens. 

  
 16 

	9.	 RIGHTS AND REMEDIES 

 9.1 Rights and Remedies. 
 (a) Upon the occurrence
and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of any Lender shall, without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to any Borrower,
(ii) by notice to any Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or
the Lenders) or (iii) by notice to any Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for any Borrower’s benefit under this Agreement or under any other agreement between a Borrower
and Collateral Agent and/or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for a Borrower’s benefit under this Agreement or under any other
agreement between a Borrower and Collateral Agent and/or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders). 
 (b) Without limiting the rights of the Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance of an Event of Default Collateral Agent shall
have the right at the written direction of the Required Lenders, without notice or demand, to do any or all of the following: 
 (i) foreclose upon and/or sell or otherwise liquidate, the Collateral; 
 (ii) apply to the Obligations (a) any balances and deposits of any Borrower that Collateral Agent or any Lender holds or controls, or (b) any amount held or controlled by Collateral Agent or any
Lender owing to or for the credit or the account of any Borrower; and/or 
 (iii) commence and prosecute an
Insolvency Proceeding or consent to any Borrower commencing any Insolvency Proceeding. 
 (c) Without limiting
the rights of the Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the continuance of an Event of Default Collateral Agent shall have the right, without notice or demand, to do any or
all of the following: 
 (i) settle or adjust disputes and claims directly with Account Debtors for amounts on
terms and in any order that Collateral Agent considers and/or any Lender considers advisable, notify any Person owing any Borrower money of Collateral Agent’s security interest in such funds, and verify the amount of such account; 

(ii) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its
security interest in the Collateral. Borrowers shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates. Collateral Agent may enter premises where the Collateral is
located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Each Borrower grants Collateral
Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral Agent’s rights or remedies; 
 (iii) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral. Collateral Agent is hereby granted a non-exclusive, royalty-free license or
other right to use, without charge, Borrowers’ labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the
Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent’s exercise of its rights under this Section 9. 1, Borrowers’ rights under all licenses and all
franchise agreements inure to Collateral Agent, for the benefit of the Lenders ; 

  
 17 

 (iv) place a “hold” on any account maintained with Collateral
Agent or the Lenders and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 

(v) demand and receive possession of Borrower’s Books; 

(vi) appoint a receiver to sieze, manage and realize any of the Collateral, and such receiver shall have any right and
authority as any competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of each Borrower; and 

(vii) Subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Collateral Agent under the Loan
Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 
 Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in
this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance. As used in the immediately preceding sentence, “Exigent Circumstance” means any event or circumstance that, in the
reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof,
destruction or material waste thereof, or failure of any Borrower after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a
material diminution in value of the Collateral. 
 9.2 Power of Attorney. Each Borrower hereby
irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security;
(b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms
Collateral Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the
Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits. Borrower
hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of Collateral Agent’s security interest in the Collateral regardless of whether an
Event of Default has occurred until all Obligations (other than inchoate indemnity obligations) have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to make Credit Extensions hereunder. Collateral
Agent’s foregoing appointment as Borrower’s attorney in fact, and all of Collateral Agent’s rights and powers in connection herewith, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity
obligations) have been fully repaid and performed and Collateral Agent’s and the Lenders’ obligation to provide Credit Extensions terminates. 
 9.3 Protective Payments. If any Borrower fails to obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which any Borrower is
obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders’ Expenses and immediately due and payable, bearing
interest at the Default Rate, and secured by the Collateral. Collateral Agent will make reasonable efforts to provide Parent with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within
a reasonable time thereafter. No such payments by Collateral Agent are deemed an agreement to make similar payments in the future or Collateral Agent’s waiver of any Event of Default. 

9.4 Application of Payments and Proceeds. Notwithstanding anything to the contrary contained in this Agreement,
upon the occurrence and during the continuance of an Event of Default, (a) each Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or on
behalf of any Borrower of all or any part of the Obligations, and, as between a Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing

  
 18 

 
and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by
Collateral Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders’ Expenses; second, to accrued and unpaid interest on the Obligations (including any
interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of any Borrower
owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to Parent or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out
the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular
category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or
obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as
may be necessary to ensure the ratable repayment of each Lender’s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by any Borrower. Notwithstanding the foregoing, a Lender receiving a
scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled
payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or
distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be
received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders’ claims. To the extent any payment for the account of a Borrower is required to be
returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such
Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent’s security interest therein. 

9.5 Liability for Collateral. So long as Collateral Agent and the Lenders comply with reasonable banking practices
regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any
loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Subject to the immediately preceding sentence. Borrowers bear all risk of
loss, damage or destruction of the Collateral. 
 9.6 No Waiver; Remedies Cumulative. Collateral
Agent’s failure, at any time or times, to require strict performance by any Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent thereafter to demand strict
performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Collateral Agent and then is only effective for the specific instance and purpose for which it is given. Collateral Agent’s rights and
remedies under this Agreement and the other Loan Documents are cumulative. Collateral Agent has all rights and remedies provided under the Code, any applicable law, by law, or in equity. Collateral Agent’s exercise of one right or remedy is not
an election, and Collateral Agent’s waiver of any Event of Default is not a continuing waiver. Collateral Agent’s delay in exercising any remedy is not a waiver, election, or acquiescence. 

9.7 Demand Waiver. Each Borrower waives, to the fullest extent permitted by law, demand, notice of default or
dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Collateral Agent on which
any Borrower is liable. 
 9.8 Borrower Liability. Either Borrower may, acting singly, request Term Loans
hereunder. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Term Loans hereunder. Each Borrower hereunder shall be jointly and severally obligated to repay all Term Loans
made hereunder, regardless of which Borrower actually receives said Term Loan, as if each Borrower 

  
 19 

 
hereunder directly received all Term Loans. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, and (b) any right to require
Collateral Agent to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Collateral Agent may exercise or not exercise any right or remedy it has
against any Borrower or any security it holds (including the right to foreclose by judicial or nonjudicial sale) without affecting any Borrower’s liability. Notwithstanding any other provision of this Agreement or other related document, until
the Obligations (other than inchoate indemnity obligations) have been indefeasibly satisfied in full, in cash, and Lenders no longer have a commitment to make Credit Extensions hereunder, each Borrower irrevocably waives all rights that it may have
at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other
Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or
to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other
arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Collateral Agent and such payment shall be promptly delivered
to Collateral Agent for application to the Obligations, whether matured or unmatured. 
  

	10.	 NOTICES 

 All notices, consents, requests, approvals, demands, or other communication (collectively, “Communication”) by any party to this Agreement or any other Loan Document must be in writing
and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail or Canadian mail, first class, registered or certified mail return
receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight
courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Collateral
Agent, Lender or Borrowers may change its mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10. 

 

			
	 If to Borrowers:
	  	 PROTOX THERAPEUTICS INC.

		  	 1500 – 885 West Georgia Street

		  	 Vancouver, British Columbia, Canada, V6C 3E8

		  	 Attn: Executive Chairman, President

		  	 Fax: (604) 688-0173

		  	 Email: Lars@Cebix.com

		
	 with a copy to:
	  	 Fasken Martineau DuMoulin LLP

		  	 Iain Mant

		  	 2900-550 Burrard Street

		  	 Vancouver, BC V6C 0A3 Canada

		  	 Attn: Iain Mant

		  	 Fax: (604) 632-4734

		  	 Email: imant@fasken.com

		
	 If to Collateral Agent:
	  	 Oxford Finance LLC

		  	 133 North Fairfax Street

		  	 Alexandria, Virginia 22314

		  	 Attention: General Counsel

		  	 Fax: (703) 519-5225

		
	 with a copy to:
	  	 DLA Piper LLP (US)

		  	 4365 Executive Drive, Suite 1100

		  	 San Diego, California 92121-2133

  
 20 

			
		  	 Attn: Troy Zander

		  	 Fax: (858) 638-5086

		  	 Email: troy.zander@dlapiper.com

		
	 and a copy to:
	  	 Aird & Berlis LLP

		  	 Brookfield Place • 181 Bay Street

		  	 Suite 1800 • Box 754

		  	 Toronto ON • M5J 2T9 • Canada

		  	 Attn: Tony Gioia

		  	 Fax: (416) 863-1515

		  	 Email: tgioia@airdberlis.com

  

	11.	 CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

New York law governs the Loan Documents (other than the Blocked Account Agreement) without regard to principles of
conflicts of law. Each Borrower, Lenders and Collateral Agent each submit to the exclusive jurisdiction of the State and Federal courts in the City of New York, Borough of Manhattan. NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND LENDERS SHALL
HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST ANY BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO
REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT’S AND LENDERS’ RIGHTS AGAINST ANY BORROWER OR ITS PROPERTY. Each Borrower expressly submits and consents in advance to such jurisdiction in any action or suit commenced in
any such court, and each Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed
appropriate by such court. Each Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or
certified mail addressed to Borrowers at the address set forth in Section 10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of any Borrower’s actual receipt thereof or three (3) days
after deposit in the U.S. mails, first class, registered or certified mail return receipt requested, proper postage prepaid. 

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH BORROWER, COLLATERAL AGENT, AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL
OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES TO
ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
  

	12.	 GENERAL PROVISIONS 

 12.1 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party. No Borrower may transfer, pledge or assign this Agreement or any
rights or obligations under it without Collateral Agent’s prior written consent (which may be granted or withheld in Collateral Agent’s discretion, subject to Section 12.6). The Lenders have the right, without the consent of or notice
to any Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in (any such sale, transfer, assignment, negotiation, or grant of a participation, a “Lender Transfer”) all or any part of, or any interest in, the
Lenders’ obligations, rights, and benefits under this Agreement and the other Loan Documents provided, however, that any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible Assignee) of its
obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an “Approved Lender”); provided further that
provided no Event of Default has occurred and is continuing, no Lender Transfer may be made to any direct or indirect competitor of Borrowers, or any Affiliate of a competitor of Borrowers or a vulture hedge fund, in each case as determined by
Collateral Agent in its reasonable discretion, without Borrowers’ prior written consent. Borrowers and Collateral 

  
 21 

 
Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective
assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee or Approved Lender as Collateral
Agent reasonably shall require. 
 12.2 Indemnification. Each Borrower agrees to indemnify, defend and
hold Collateral Agent and the Lenders and their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an “Indemnified Person”)
harmless against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”) asserted by any other party in connection with the transactions contemplated by the Loan Documents; and (b) all losses or
Lenders’ Expenses incurred, or paid by Indemnified Person from, following, or arising from transactions between Collateral Agent, and/or the Lenders and any Borrower (including reasonable attorneys’ fees and expenses), except as to
(a) or (b) for Claims and/or losses and/or expenses (including Lenders’ Expenses) directly caused by such Indemnified Person’s gross negligence or willful misconduct. Each Borrower hereby further indemnifies, defends and holds
each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and
disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding not caused by gross negligence or willful misconduct of such Indemnified Person, whether
or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of any Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar
technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on,
incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds. 

12.3 Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 

12.4 Severability of Provisions. Each provision of this Agreement is severable from every other provision in
determining the enforceability of any provision. 
 12.5 Correction of Loan Documents. Collateral Agent
and the Lenders may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents in a manner consistent with the agreement of the parties so long as Collateral Agent provides Parent with written notice of such
correction and allows Parent at least ten (10) days to object to such correction. In the event of such objection, such correction shall not be made except by an amendment signed by both Collateral Agent and Borrowers. 

12.6 Amendments in Writing; Integration. (a) No amendment, modification, termination or waiver of any
provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent to any departure by any Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by Parent,
Collateral Agent and the Required Lenders provided that: 
 (i) no such amendment, waiver or other modification
that would have the effect of increasing or reducing a Lender’s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender’s written consent; 

(ii) no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be
effective without Collateral Agent’s written consent or signature; 
 (iii) no such amendment, waiver or
other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or
fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder
(other than late charges or 

  
 22 

 
for any termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for Lenders to take any action
hereunder; (D) release all or substantially all or any material portion of the Collateral, authorize any Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any guarantor of all
or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in
connection with any disposition permitted hereunder); (E) amend, waive or otherwise modify this Section 12.6 or the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance of this
Section 12.6; (F) consent to the assignment, delegation or other transfer by a Borrower of any of its rights and obligations under any Loan Document or release any Borrower of its payment obligations under any Loan Document, except, in
each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions Pro Rata Share, Term Loan Commitment,
Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations;
or (I) amend any of the provisions of Section 12.10. It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C),
(D), (E), (F), (G) and (H) of the preceding sentence; 
 (iv) the provisions of the foregoing clauses
(i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the Lenders and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or
modification of the Loan Documents only in the event of the unanimous agreement of all Lenders. 
 (b) Other
than as expressly provided for in Section 12.6(a)(i)-(iii), Collateral Agent may, if requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative of Parent.

 (c) This Agreement and the Loan Documents represent the entire agreement about this subject matter and
supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the
Loan Documents. 
 12.7 Counterparts. This Agreement may be executed in any number of counterparts and by
different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. 
 12.8 Survival. All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than
inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied. The obligation of Borrowers in Section 12.2 to indemnify each Lender and Collateral Agent, as
well as the confidentiality provisions in Section 12.9 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run. 

12.9 Confidentiality. Each of the Lenders and the Collateral Agent shall keep confidential and not disclose or
divulge any confidential information of any Borrower and shall exercise the same degree of care that it exercises for their own proprietary information; however, disclosure of confidential information may be made: (a) to the Lenders’ and
Collateral Agent’s Subsidiaries or Affiliates; (b) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Collateral Agent shall use commercially reasonable efforts to obtain
such prospective transferee’s or purchaser’s agreement to the terms of this provision); (c) as required by law, regulation, subpoena, or other order; (d) to Lenders’ or Collateral Agent’s regulators or as otherwise
required in connection with an examination or audit; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents; and (f) to third party service providers of the Lenders and/or Collateral Agent
so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less restrictive than those contained herein. Confidential information does not include information that either:
(i) is in the public domain or in the Lenders’ and/or Collateral Agent’s possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of the public domain after

  
 23 

 
disclosure to the Lenders and/or Collateral Agent through no fault of any Lender or the Collateral Agent; or (ii) is disclosed to the Lenders and/or Collateral Agent by a third party, if the
Lenders and/or Collateral Agent does not know that the third party is prohibited from disclosing the information. Subject to the foregoing provisions of this Section 12.9, Collateral Agent and the Lenders may use confidential information for
any purpose, including, without limitation, for the development of client databases, reporting purposes, and market analysis, so long as Collateral Agent does not disclose Borrowers’ identity or the identity of any person associated with any
Borrower unless otherwise expressly permitted by this Agreement. The provisions of the immediately preceding sentence shall survive the termination of this Agreement. 

12.10 Right of Set Off. Each Borrower hereby grants to Collateral Agent and to each Lender, a lien, security
interest and right of set off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all of the rights, titles and interests of such Borrower in deposits, credits,
collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit
to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation
of Borrowers even though unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES
THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF ANY BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

12.11 Electronic Execution of Documents. The words “execution,” “signed,”
“signature” and words of like import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a
manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions
Act. 
 12.12 Captions. The headings used in this Agreement are for convenience only and shall not affect
the interpretation of this Agreement. 
 12.13 Construction of Agreement. The parties mutually
acknowledge that they and their attorneys have participated in the preparation and negotiation of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist.

 12.14 Relationship. The relationship of the parties to this Agreement is determined solely by the
provisions of this Agreement. The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary or other relationship with duties or incidents different from those of parties to an arm’s-length contract. 

12.15 Third Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) confer any
benefits, rights or remedies under or by reason of this Agreement on any persons other than the express parties to it and their respective permitted successors and assigns; (b) relieve or discharge the obligation or liability of any person not
an express party to this Agreement; or (c) give any person not an express party to this Agreement any right of subrogation or action against any party to this Agreement. 

 

	13.	 COLLATERAL AGENT 

 13.1 Appointment and Authorization of Collateral Agent. Each Lender hereby irrevocably appoints, designates and authorizes Collateral Agent to take such action on its behalf under the provisions of
this Agreement and each other Loan Document and to exercise such powers and perform such duties as are expressly delegated to it by the terms of this Agreement or any other Loan Document, together with such powers as are reasonably incidental
thereto. Notwithstanding any provision to the contrary contained elsewhere herein or in any other Loan Document, Collateral Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall Collateral Agent have
or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into 

  
 24 

 
this Agreement or any other Loan Document or otherwise exist against Collateral Agent. Without limiting the generality of the foregoing sentence, the use of the term “agent” herein and
in the other Loan Documents with reference to Collateral Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law. Instead, such term is used merely as a matter of
market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties. 
 13.2 Delegation of Duties. Collateral Agent may execute any of its duties under this Agreement or any other Loan Document by or through itself, or its agents or attorneys-in-fact and shall be
entitled to obtain and rely upon the advice of counsel and other consultants or experts concerning all matters pertaining to such duties. Collateral Agent shall not be responsible for the negligence or misconduct of any agent or attorney-in-fact
that it selects in the absence of gross negligence or willful misconduct. 
 13.3 Liability of Collateral
Agent. Except as otherwise provided herein, no Collateral Agent-Related Person shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the
transactions contemplated hereby (except for its own gross negligence or willful misconduct in connection with its duties expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement,
representation or warranty made by any Borrower or any officer thereof, contained herein or in any other Loan Document, or in any certificate, report, statement or other document referred to or provided for in, or received by Collateral Agent under
or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document, or for any failure of any Borrower or any other party to any
Loan Document to perform its obligations hereunder or thereunder. No Collateral Agent-Related Person shall be under any obligation to any Lender or participant to ascertain or to inquire as to the observance or performance of any of the agreements
contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of any Borrower or any Affiliate thereof. 

13.4 Reliance by Collateral Agent. Collateral Agent may rely, and shall be fully protected in acting, or
refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or
presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties. In the absence of its gross negligence or willful misconduct, Collateral Agent may conclusively rely, as to
the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Collateral Agent and conforming to the requirements of the Loan Agreement or any of the other Loan Documents.
Collateral Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Collateral Agent hereunder or under any Loan
Documents in accordance therewith. Collateral Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction. Collateral Agent shall not be under any obligation to
exercise any of the rights or powers granted to Collateral Agent by this Agreement and the other Loan Documents at the request or direction of Lenders unless Collateral Agent shall have been provided by Lenders with adequate security and indemnity
against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction. 
 13.5 Notice of Default. Unless the officers of Collateral Agent acting in their capacity as officer of Collateral Agent on any Borrower’s account have actual knowledge thereof or have been
notified in writing thereof by Lenders, Collateral Agent shall not be required to ascertain or inquire as to the existence or possible existence of any Event of Default. Collateral Agent shall not be deemed to have knowledge or notice of the
occurrence of any default and/or Event of Default, unless Collateral Agent shall have received written notice from a Lender or a Borrower, describing such default or Event of Default. Collateral Agent will notify the Lenders of its receipt of any
such notice. Collateral Agent shall take such action with respect to an Event of Default as may be determined by Lenders in accordance with the terms of Section 9(a); provided, however, that while an Event of Default has occurred and is
continuing, Collateral Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default as Collateral Agent shall deem advisable or in the best interest of the Lenders, including
without limitation, satisfaction of other security interests, liens or encumbrances on the Collateral not permitted under the Loan Documents, payment of taxes on behalf of a Borrower, payments to landlords, warehouseman, bailees and other persons in
possession of the Collateral and other actions to protect and 

  
 25 

 
safeguard the Collateral, and actions with respect to insurance claims for casualty events affecting any Borrower and/or the Collateral. 

13.6 Credit Decision; Disclosure of Information by Collateral Agent. Each Lender acknowledges that no Collateral
Agent-Related Person has made any representation or warranty to it, and that no act by Collateral Agent hereafter taken, including any consent to and acceptance of any assignment or review of the affairs of any Borrower or any Affiliate thereof,
shall be deemed to constitute any representation or warranty by any Collateral Agent-Related Person to any Lender as to any matter, including whether Collateral Agent-Related Persons have disclosed material information in their possession. Each
Lender represents to Collateral Agent that it has, independently and without reliance upon any Collateral Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own appraisal of, and investigation
into, the business, prospects, operations, property, financial and other condition and creditworthiness of each Borrower and its respective Subsidiaries, and all applicable bank or other regulatory laws relating to the transactions contemplated
hereby, and made its own decision to enter into this Agreement and to extend credit to Borrowers hereunder. Each Lender also represents that it will, independently and without reliance upon any Collateral Agent-Related Person and based on such
documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigations
as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrowers. Except for notices, reports and other documents expressly required to be furnished to the
Lenders by Collateral Agent herein, Collateral Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial and other condition or
creditworthiness of any Borrower or any of its Affiliates which may come into the possession of any Collateral Agent-Related Person. 
 13.7 Indemnification of Collateral Agent. Each Lender severally, but not jointly, agrees (a) to indemnify and hold Collateral Agent (and each Collateral Agent-Related Person) harmless from and
against and (b) promptly upon receipt by each Lender of Collateral Agent’s statement, to reimburse Collateral Agent, according to such Lender’s Pro Rata Share, to the extent Collateral Agent shall not otherwise have been reimbursed by
Borrowers on account of and for, any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses (including, without limitation, the fees and disbursements of counsel and other advisors) or disbursements
of any kind of nature whatsoever with respect to Collateral Agent’s performance of its duties under this Agreement and the other Loan Documents; provided, however, that no Lender shall be liable for the payment to Collateral Agent of any
portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements resulting solely from Collateral Agent’s gross negligence or willful misconduct. Such reimbursement shall not in
any respect release any Borrower from any liability or obligation. If any indemnity furnished to Collateral Agent for any purpose shall, in the opinion of Collateral Agent, be insufficient or become impaired, Collateral Agent may call for additional
indemnity and cease, or not commence, to do the acts indemnified against until such additional indemnity is furnished. Collateral Agent’s right to indemnification shall survive termination of this Agreement. 

13.8 Collateral Agent in its Individual Capacity. With respect to its Credit Extensions, Oxford shall have the
same rights and powers under this Agreement as any other Lender and may exercise such rights and powers as though it were not Collateral Agent, and the terms “Lender” and “Lenders” include Oxford in its individual capacity.

 13.9 Successor Collateral Agent. Collateral Agent may resign at any time by giving thirty
(30) days’ prior written notice thereof to Lenders and Parent; provided, however, that the retiring Collateral Agent shall continue to serve until a successor Collateral Agent shall have been selected and approved pursuant to this
Section 13.19. Upon any such notice, Collateral Agent shall have the right to appoint, subject to the consent of Lenders, a successor Collateral Agent. Without limitation of the foregoing, if Collateral Agent becomes insolvent or commits any
act or omission constituting gross negligence or willful misconduct of its duties as Collateral Agent hereunder, then the Lenders shall have the right to replace the Collateral Agent. Upon the acceptance of its appointment as successor Collateral
Agent hereunder, the Person acting as such successor Collateral Agent shall succeed to all the rights, powers and duties of the retiring Collateral Agent and the respective term “Collateral Agent” means such successor Collateral Agent and
the retiring Collateral Agent’s appointment, powers and duties in such capacities shall be terminated without any other further act or deed on its behalf. After any retiring Collateral Agent’s

  
 26 

 
resignation hereunder as Collateral Agent, the provisions of this Article 13 and Section 12.2 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was
Collateral Agent under this Agreement. 
 13.10 Proofs of Claim. In case of any Insolvency Proceeding
relative to any Borrower, each Lender shall promptly file a claim or claims, on the form required in such proceeding, for the full outstanding amount of such Lender’s claim, and shall use its best efforts to cause said claim or claims to be
approved and each of the Lenders hereby irrevocably agrees that, to the extent that it fails timely to do so, any other Lender may in the name of the first Lender, or otherwise, prove up (but not vote) any and all claims of the first Lender relating
to the first Lender’s claim. 
 13.11 Collateral and Guaranty Matters. The Lenders irrevocably
authorize Collateral Agent, at its option and in its discretion, to release any guarantor and any Lien on any Collateral granted to or held by Collateral Agent under any Loan Document (i) upon the date that all Obligations due hereunder have
been fully and indefeasibly paid in full and no Term Loan Commitments or other obligations of any Lender to provide funds to any Borrower under this Agreement remain outstanding, (ii) that is transferred or to be transferred as part of or in
connection with any Transfer permitted hereunder or under any other Loan Document, or (iii) as approved in accordance with Section 12.6. Upon request by Collateral Agent at any time, all Lenders will confirm in writing Collateral
Agent’s authority to release its interest in particular types or items of Property, pursuant to this Section 13.11. 
 13.12 Cooperation of Borrowers. If necessary, each Borrower agrees to (i) execute any documents (including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each
assignment of a Term Loan Commitment or Term Loan to an assignee in accordance with Section 12.1, (ii) make Borrower’s management available to meet with Collateral Agent and prospective participants and assignees of Term Loan
Commitments or Credit Extensions (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of
information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request. Subject to the provisions of Section 12.9 Borrower authorizes each Lender to
disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower
pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this Agreement. 

 

	14.	 DEFINITIONS 

 14.1 Definitions. As used in this Agreement, the following terms have the following meanings: 
 “Account” is any “account” as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other
sums owing to a Borrower. 
 “Account Debtor” is any “account debtor” as defined in
the Code with such additions to such term as may hereafter be made. 
 “Affiliate” of any
Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and,
for any Person that is a limited liability company, that Person’s managers and members. 

“Agreement” is defined in the preamble hereof. 

“Amortization Date” is June 1, 2012. 

  
 27 

 “Anti-Terrorism Laws” means any laws relating to terrorism
or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC. 

“Approved Fund” means any (i) investment company, fund, trust, securitization vehicle or conduit
that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii) any Person (other than a natural person) which temporarily
warehouses loans for any Lender or any entity described in the preceding clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or
(c) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender. 
 “Approved Lender” has the meaning given it in Section 12.1. 
 “Basic Rate” means the per annum rate of interest (based on a year of 360 days) equal to the greater of (i) nine and one half percent (9.50%) and (ii) the sum of
(a) the three (3)-month U.S. LIBOR rate reported in the Wall Street Journal three (3) Business Days prior to the Funding Date of such Term Loan (provided that such rate shall have a floor of one percent (1.00%)), plus (b) eight
and one half percent (8.50%). 
 “Blocked Person” means any Person: (a) listed in the
annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of,
Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports
“terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list.

 “Borrower” and “Borrowers” is defined in the preamble hereof. 

“Borrower’s Books” are all of a Borrower’s books and records including ledgers, federal, state
and provincial tax returns, records regarding such Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. 

“Business Day” is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.

 “Cash Equivalents” are (a) marketable direct obligations issued or unconditionally
guaranteed by the United States or any agency or any State thereof or Canada or any agency or any Province thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one
(1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc., and (c) certificates of deposit maturing no more than one (1) year after
issue provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent and (d) money market funds at least ninety-five percent (95%) of the assets of which
constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition. For the avoidance of doubt, the direct purchase by any Borrower, co-borrower, or any subsidiary of a Borrower of any auction rate securities,
or purchasing participations in, or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of auction rate security by a Borrower, co-borrower, or any subsidiary of a
Borrower shall be conclusively determined by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this Agreement governing Permitted Investments. Notwithstanding the foregoing, Cash
Equivalents does not include and each Borrower and its Subsidiaries are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any
ownership interest in any type of debt instrument, including, without limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an
auction rate security. 
 “Claims” are defined in Section 12.2. 

  
 28 

 “Code” is (a) with respect to Protox US or any assets
located in the United States, the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document
and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any
or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term
“Code” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of
definitions relating to such provisions, and (b) with respect to Parent or any assets located in Canada, the Personal Property Security Act (British Columbia) or other applicable laws of the Province of British Columbia and the laws of Canada
applicable thereto, as amended and as may be further amended and in effect from time to time; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies
with respect to, Collateral Agent’s Lien on any Collateral is governed by the Personal Property Security Act or equivalent legislation in effect in a provincial jurisdiction other than British Columbia, the term “Code” shall mean the
Personal Property Security Act or equivalent legislation as enacted and in effect in such other province solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions
relating to such provisions. 
 “Collateral” is any and all properties, rights and assets of
each Borrower described on Exhibit A and any and all other properties, rights and assets of each Borrower granted by Borrowers to Collateral Agent, for the ratable benefit of the Lenders, or arising under the Code or other applicable
law, now, or in the future. 
 “Collateral Account” is any Deposit Account, Securities Account,
or Commodity Account. 
 “Collateral Agent” means, Oxford, not in its individual capacity, but
solely in its capacity as agent on behalf of and for the benefit of the Lenders. 
 “Collateral
Agent-Related Person” means the Collateral Agent, together with its Affiliates, and the officers, directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided, however, that no Collateral Agent-Related
Person shall be an Affiliate of any Borrower. 
 “Commitment Percentage” is set forth in
Schedule 1.1, as amended from time to time. 
 “Commodity Account” is any “commodity
account” as defined in the Code with such additions to such term as may hereafter be made. 

“Communication” is defined in Section 10. 

“Compliance Certificate” is that certain certificate in the form attached hereto as Exhibit
C. 
 “Contingent Obligation” is, for any Person, any direct or indirect liability,
contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that
Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap agreement,
interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not include
endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably
anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” is any control agreement entered into among the depository institution at which any
Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which any 

  
 29 

 
Borrower maintains a Securities Account or a Commodity Account, the relevant Borrower, and Collateral Agent pursuant to which Collateral Agent obtains control (within the meaning of the Code) for
the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account or, as the context may require, a blocked accounts agreement entered into among RBC, Collateral Agent and Parent with respect to certain depositary
accounts and disbursement accounts described therein. 
 “Credit Extension” is any Term Loan or
any other extension of credit by Collateral Agent or Lenders for any Borrower’s benefit. 

“Default Rate” is defined in Section 2.3(b). 

“Deposit Account” is any “deposit account” as defined in the Code with such additions to such
term as may hereafter be made. 
 “Designated Deposit Account” is Parent’s deposit
account, account number 00010 4001145, maintained with RBC. 
 “Dollars,”
“dollars” and “$” each mean lawful money of the United States. 

“Effective Date” is defined in the preamble of this Agreement. 

“Eligible Assignee” means (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved
Fund and (iv) any commercial bank, savings and loan association or savings bank or any other entity which is an “accredited investor” (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit
or buys loans as one of its businesses, including insurance companies, mutual funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard & Poor’s
Rating Group and a rating of Baa2 or higher from Moody’s Investors Service, Inc. at the date that it becomes a Lender or (B) has total assets in excess of $5,000,000,000, and in each case of clauses (i) through (iv), which, through
its applicable lending office, is capable of lending to Borrowers without the imposition of any withholding or similar taxes; provided that notwithstanding the foregoing, “Eligible Assignee” shall not include (i) any Borrower, any
guarantor or any of a Borrower’s or any such guarantor’s Affiliates or Subsidiaries or (ii) unless an Event of Default has occurred and is continuing, a direct competitor of a Borrower or a guarantor or a vulture hedge fund, each as
determined by Collateral Agent in its reasonable discretion. Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein
shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender’s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any
Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such
Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form
satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require. 

“Equipment” is all “equipment” as defined in the Code with such additions to such term as may
hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

“ERISA” is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.

 “Event of Default” is defined in Section 8. 

“Final Payment” is a payment (in addition to and not a substitution for the regular monthly payments of
principal plus accrued interest) due on the earliest to occur of (a) the Maturity Date, or (b) the acceleration of any Term Loan, or (c) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d), equal to the original
principal 

  
 30 

 
amount of such Term Loan multiplied by the Final Payment Percentage, payable to (and for the sole account of) Oxford. 

“Final Payment Percentage” is five percent (5.00%). 

“Funding Date” is any date on which a Credit Extension is made to or on account of Borrowers which shall
be a Business Day. 
 “GAAP” is (a) with respect to Protox US, generally accepted
accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such
other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination, and (b) with respect to Parent, generally accepted
accounting principles from time to time approved by the Canadian Institute of Chartered Accountants, or any successor entity thereto, applicable as at the date on which such principles are to be applied or on which any calculation or determination
is required to be made in accordance with generally accepted accounting principles, consistently applied. 

“General Intangibles” is all “general intangibles” as that term is used in the Uniform
Commercial Code, or “intangibles” as defined in the Personal Property Security Act (British Columbia), in each case in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation,
all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under
applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer
lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in
contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind. 

“Governmental Approval” is any consent, authorization, approval, order, license, franchise, permit,
certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 
 “Governmental Authority” is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or
other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization. 

“Indebtedness” is (a) indebtedness for borrowed money or the deferred price of property or
services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations.

 “Indemnified Person” is defined in Section 12.2. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy
Code, the Bankruptcy and Insolvency Act (Canada) or the Companies’ Creditors Arrangement Act (Canada), or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions
generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” includes without limitation, all copyright rights, copyright applications,
copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals,
reissues, extensions, and continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or

  
 31 

 
not, and the goodwill of the business of any Person connected with and symbolized thereby, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented
inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing. 
 “Inventory” is all “inventory” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation all
merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of any Person’s custody or possession or in transit and
including any returned goods and any documents of title representing any of the above. 

“Investment” is any beneficial ownership interest in any Person (including stock, partnership interest
or other securities), and any loan, advance or capital contribution to any Person. 
 “Investment
Letter” is that certain letter agreement, dated as of the Effective Date, in form and content reasonably acceptable to the Lenders, pursuant to which Parent grants to Lenders or their Affiliates a right (but not an obligation) to invest up
to One Million Dollars ($1,000,000) in the aggregate, to be divided between the Lenders in accordance with their respective Pro Rata Share, in any of Parent’s rounds of private equity financing on the terms, conditions and pricing set forth
therein. 
 “IP Agreement” is that certain Intellectual Property Security Agreement entered
into by and between each Borrower and Collateral Agent dated as of the Effective Date, as such may be amended from time to time. 
 “Key Person” means Parent’s Executive Chairman, who is Lars Ekman as of the Effective Date. 
 “Lender” is any one of the Lenders. 

“Lenders” shall mean the Persons identified on Schedule 1.1 hereto and each assignee that becomes a
party to this Agreement pursuant to Section 12.1. 
 “Lenders’ Expenses” are all
audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating,
administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan
Documents. 
 “Lien” is a claim, mortgage, deed of trust, levy, charge, pledge, security
interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property. 
 “Loan Documents” are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate, the IP Agreement, the Investment Letter, any subordination
agreements, any note, or notes or guaranties executed by any Borrower, and any other present or future agreement entered into by any Borrower for the benefit of Lenders and Collateral Agent in connection with this Agreement, all as amended,
restated, or otherwise modified. 
 “Material Adverse Change” is (a) a material impairment
in the perfection or priority of Collateral Agent’s Lien in the Collateral or in the value of such Collateral; (b) a material adverse change in the business, operations, or condition (financial or otherwise) of each Borrower; or (c) a
material impairment of the prospect of repayment of any portion of the Obligations. 
 “Maturity
Date” is the date which is thirty (30) months after the Amortization Date. 

“Obligations” are each Borrower’s obligation to pay when due any debts, principal, interest,
Lenders’ Expenses, the Prepayment Fee, the Final Payment, and other amounts any Borrower owes the Lenders now or later, whether under this Agreement, the Loan Documents (other than the Warrants), or otherwise, including, without limitation, all
obligations relating to letters of credit (including reimbursement obligations for drawn and undrawn 

  
 32 

 
letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts,
liabilities, or obligations of any Borrower assigned to the Lenders and/or Collateral Agent, and the performance of each Borrower’s duties under the Loan Documents (other than the Warrants). 

“OFAC” is the U.S. Department of Treasury Office of Foreign Assets Control. 

“OFAC Lists” are, collectively, the Specially Designated Nationals and Blocked Persons List maintained
by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other
applicable Executive Orders. 
 “Operating Documents” are, for any Person, such Person’s
formation or constating documents, as certified, if applicable, by the Secretary of State (or local equivalent) of such Person’s jurisdiction of organization on a date that is no earlier than 30 days prior to the Effective Date, and,
(a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its
partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto. 
 “Payment/Advance Form” is that certain form attached hereto as Exhibit B. 
 “Payment Date” is the first (1st) calendar day of each calendar month. “Perfection Certificate” is defined in Section 5.1. 

“Perfection Certificate” is defined in Section 5.1. 

“Permitted Indebtedness” is: 

(a) Borrowers’ Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents;

 (b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate; 

(c) Subordinated Debt; 
 (d) unsecured Indebtedness to trade creditors incurred in the ordinary course of business; 
 (e) Indebtedness secured by liens specified in clause (c) of the definition of “Permitted Liens” provided such Indebtedness shall not exceed Fifty Thousand Dollars ($50,000) in the
aggregate principal amount outstanding at any one time; 
 (f) Indebtedness incurred as a result of endorsing
negotiable instruments received in the ordinary course of Borrowers’ business; 
 (g) (i) Indebtedness of
one Borrower to another Borrower, or (ii) Indebtedness of a Borrower to a Subsidiary that is a co-Borrower or guarantor of the Obligations and Indebtedness of a Subsidiary that is a co-Borrower or guarantor of the Obligations to a Borrower;

 (h) Indebtedness consisting of interest rate, currency, or commodity swap agreements, interest rate cap or
collar agreements or arrangements entered into in the ordinary course of business and designated to protect a Borrower or its Subsidiaries against fluctuations in interest rates, currency exchange rates, or commodity prices; provided that
Borrowers’ aggregate liability thereunder shall not exceed Three Hundred Thousand Dollars ($300,000) at any time during the term of this Agreement; and 
 (i) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (h) above, provided that the principal amount thereof is not increased
or the 

  
 33 

 
terms thereof are not modified to impose materially more burdensome terms upon Borrowers or their Subsidiaries, as the case may be. 

“Permitted Investments” are: 

(a) Investments shown on the Perfection Certificate and existing on the Effective Date; and 

(b) Investments in cash and Cash Equivalents. 

(c) (i) Investments of one Borrower in another Borrower, and (ii) Investments of a Borrower in a Subsidiary that is
a co-Borrower or guarantor of the Obligations and Investments of a Subsidiary that is a co-Borrower or guarantor of the Obligations in a Borrower; 
 (d) Investments consisting of deposit accounts or securities accounts, provided that Collateral Agent has a perfected security interest in such accounts; 

(e) Investments accepted in connection with Transfers permitted by Section 7.1; 

(f) Investments approved by a Borrowers’ Board of Directors or otherwise pursuant to a Board-approved investment
policy; provided the same is provided to and approved by Collateral Agent; 
 (g) Investments consisting of
interest rate, currency, or commodity swap agreements, interest rate cap or collar agreements or arrangements entered into in the ordinary course of business and designated to protect a Person against fluctuations in interest rates, currency
exchange rates, or commodity prices; provided that Borrowers’ liability thereunder does not exceed Three Hundred Thousand Dollars ($300,000) in the aggregate at any time during the term of this Agreement; 

(h) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and
advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of a Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by
such Borrower’s Board of Directors; not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year; 
 (i) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the ordinary course of business; 
 (j) Investments consisting of notes
receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business; provided that this paragraph (j) shall not apply to Investments of a Borrower in any
Subsidiary; 
 (k) joint ventures, corporate collaborations, or strategic alliances in the ordinary course of a
Borrower’s business consisting of the licensing of technology, the development of technology or the providing of technical support, but in no event consisting of cash investments by any Borrower; provided that exclusive licenses may not result
in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United States; 

(l) the formation or acquisition of Subsidiaries after the Effective Date, subject to compliance with Section 6.12
of this Agreement; and 
 (m) Investments consisting of the endorsement of negotiable instruments for deposit or
collection or similar transactions in the ordinary course of business. 

  
 34 

 “Permitted Liens” are: 

(a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement and the
other Loan Documents; 
 (b) Liens for taxes, fees, assessments or other government charges or levies, either
not delinquent or being contested in good faith and for which Borrowers maintain adequate reserves on Borrowers’ Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended ,
and the Treasury Regulations adopted thereunder; 
 (c) purchase money Liens (i) on Equipment or other
assets subject to capital leases acquired or held by Parent incurred for financing the acquisition of the Equipment or such assets subject to capital leases, or (ii) on existing Equipment or such assets subject to capital leases when acquired,
in each case if the Lien is confined to the property and improvements and the proceeds of the Equipment or other assets subject to capital leases; provided that such Liens under this clause (c) (A) may have priority over liens granted to
Collateral Agent hereunder to the extent provided under the Code so long as the Indebtedness secured by the Liens remain outstanding and (B) may secure Indebtedness of no more than Fifty Thousand Dollars ($50,000) in the aggregate principal
amount outstanding at any one time; 
 (d) statutory Liens securing claims or demands of materialmen, mechanics,
carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided they have no priority over any of Collateral Agent’s Lien and the aggregate amount of the obligations secured by such Liens does not any time
exceed Twenty-Five Thousand Dollars ($25,000); 
 (e) leases or subleases of real property granted in the
ordinary course of business, and leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or Intellectual Property) granted in the ordinary course of a Borrower’s business, if the leases, subleases,
licenses and sublicenses do not prohibit granting Collateral Agent a security interest; 
 (f) banker’s
liens, rights of setoff and Liens in favor of financial institutions incurred made in the ordinary course of business arising in connection with each Borrower’s deposit accounts or securities accounts held at such institutions to secure solely
payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section 6.6(b) hereof; 
 (g) Liens to secure payment of workers’ compensation, employment insurance, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA);

 (h) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of
Default under Section 8.4 or 8.7; 
 (i) licenses of Intellectual Property permitted by Section 7.1
hereof; 
 (j) Liens in favor of custom and revenue authorities arising in the ordinary course of business as a
matter of law to secure the payment of custom duties in connection with the importation of goods; 
 (k)
deposits to secure the performance of bids, trade contracts (other than for borrowed money), contracts for the purchase of property, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in
each case, incurred in the ordinary course of business and not representing an obligation for borrowed money; 

(l) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and other similar
Liens affecting real property not interfering in any material respect with the ordinary course of the business of Borrowers; and 

  
 35 

 (m) Liens incurred in the extension, renewal or refinancing of the
indebtedness secured by Liens described in (a) through (l) above, but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness may not increase.

 “Person” is any individual, sole proprietorship, partnership, limited liability company,
joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Prepayment Fee” means with respect to any Term Loan subject to prepayment prior to the Maturity Date,
whether by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to: 
 (i) for a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term Loan, three percent (3.00%) of the principal
amount of such Term Loan prepaid; 
 (ii) for a prepayment made after the date which is after the first
anniversary of the Funding Date of such Term Loan through and including the second anniversary of the Funding Date of such Term Loan, two percent (2.00%) of the principal amount of the Term Loans prepaid; and 

(iii) for a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan,
one percent (1.00%) of the principal amount of the Term Loans prepaid. 
 “Pro Rata Share”
means, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate
outstanding principal amount of all Term Loans. 
 “RBC” means Royal Bank of Canada.

 “Registered Organization” is any “registered organization” as defined in the Code
with such additions to such term as may hereafter be made or a “company” in accordance with the laws of its jurisdiction of organization. 
 “Required Lenders” means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an “Original Lender”) have not assigned or transferred
any of their interests in their respective Term Loans, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loans, or (ii) at any time from and after any Original Lender has assigned or
transferred any interest in its Term Loans, Lenders holding, sixty-six percent (66%) or more of the aggregate outstanding principal balance of the Term Loans, plus, in respect of this clause (ii), (A) each Original Lender that has
not assigned or transferred any portion of its respective Term Loan and (B) each assignee of an Original Lender provided such assignee was assigned or transferred and continues to hold one hundred percent (100%) of the assigning Original
Lender’s interest in the Term Loans (in each case in respect of clauses (A) and (B) of this clause (ii), whether or not such Lender is included within the Lenders holding sixty-six percent (66%) of the Terms Loans);
provided, however, that notwithstanding the foregoing, for purposes of Section 9.1(b) hereof, “Required Lenders” means (i) for so long as all Original Lenders retain one hundred percent (100%) of their
interests in their respective Term Loans, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loans, or (ii) at any time from and after any Original Lender has assigned or transferred any
interest in its Term Loans, Lenders holding, sixty-six percent (66%) or more of the aggregate outstanding principal balance of the Term Loans, plus, in respect of this clause (ii), each Original Lender that has not assigned or transferred any
portion of its respective Term Loan (in each case in respect of this clause (ii), whether or not such Original Lender is included within the Lenders holding sixty-six percent (66%) of the Term Loans). For purposes of this definition only, a
Lender shall be deemed to include itself, and any Lender that is an Affiliate or Approved Fund of such Lender. 

“Requirement of Law” is as to any Person, the organizational or governing documents of such Person, and
any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other 

  
 36 

 
Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. 

“Responsible Officer” is any of the President, Chief Executive Officer, or Chief Financial Officer of
any Borrower acting alone. 
 “Secured Promissory Note” is defined in Section 2.4.

 “Secured Promissory Note Record” is a record maintained by each Lender with respect to the
outstanding Obligations owed by Borrowers to Lender and credits made thereto. 
 “Securities
Account” is any “securities account” as defined in the Code with such additions to such term as may hereafter be made. 
 “Shares” means one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by a Borrower in any Subsidiary;
provided that, in the event such Borrower demonstrates to Collateral Agent’s reasonable satisfaction, that a pledge of more than sixty five percent (65%) of the Shares of a Subsidiary of such Borrower which is not an entity organized under
the laws of the United States or any territory thereof, creates a present and existing adverse tax consequence to such Borrower under the U.S. Internal Revenue Code, “Shares” shall mean sixty-five percent (65%) of the issued and
outstanding capital stock, membership units or other securities owned or held of record by such Borrower in such Subsidiary. 
 “Subordinated Debt” is indebtedness incurred by a Borrower subordinated to all of Borrowers’ now or hereafter indebtedness to the Lenders (pursuant to a subordination, intercreditor,
or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between Collateral Agent, Borrowers, and the other creditor), on terms acceptable to Collateral Agent and the Lenders. 

“Subsidiary” means, with respect to any Person, any Person of which more than 50.0% of the voting shares
or stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or one or more of Affiliates of such Person. 

“Term Loan” is defined in Section 2.2(a) hereof. 

“Term Loan Commitment” means, for any Lender, the obligation of such Lender to make a Term Loan, up to
the principal amount shown on Schedule 1.1. “Term Loan Commitments” means the aggregate amount of such commitments of all Lenders. 

“Transfer” is defined in Section 7.1. 

“Warrants” are those certain Warrants to Purchase Common Shares dated as of the Effective Date executed
by Parent in favor of Lenders. 
 [Signature Page to Follow] 

  
 37 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the Effective Date. 
  

									
	BORROWERS:	 	
		
	PROTOX THERAPEUTICS INC.	 	PROTOX THERAPEUTICS CORP.
					
	 By
	 	 /s/ Allison Hulme
	 		 	 By
	 	 /s/ Allison Hulme

	 Name:
	 	 Allison Hulme
	 		 	 Name:
	 	 Allison Hulme

	 Title:
	 	 Chief Operating Officer
	 		 	 Title:
	 	 Chief Operating Officer

	
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC, as Collateral Agent and as a Lender
					
	 By
	 	  
	 		 		 	
	 Name:
	 	  
	 		 		 	
	 Title:
	 	  
	 		 		 	

  
  
 [Signature Page to Loan and Security Agreement] 

  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed as of the Effective Date. 
  

											
	BORROWERS:	 		 	
			
	PROTOX THERAPEUTICS INC.	 		 	PROTOX THERAPEUTICS CORP.
					
	 By
	 	  
	 		 	 By
	 	  

	 Name:
	 	  
	 		 	 Name:
	 	  

	 Title:
	 	  
	 		 	 Title:
	 	  

	
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC, as Collateral Agent and as a Lender
					
	 By
	 	 /s/ T.A. Lex
	 		 		 	
	 Name:
	 	 T.A. Lex
	 		 		 	
	 Title:
	 	 COO
	 		 		 	

  
 [Signature Page to Loan and
Security Agreement] 

 SCHEDULE 1.1 

LENDERS AND COMMITMENTS 
 Term Loans 
  

									
	 Lender
	  	Term Loan
Commitment	 	  	Commitment
Percentage	 
	 Oxford Finance LLC
	  	$	15,000,000	  	  	 	100.00	% 
	 TOTAL
	  	$	15,000,000	  	  	 	100.00	% 

  

 EXHIBIT A 

The Collateral consists of all of each Borrower’s right, title and interest in and to the following personal property: 

All of such Borrower’s present and after acquired personal property including, without limitation, goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory
notes), chattel paper (whether tangible or electronic), cash, deposit accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment
property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and 
 All Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and
improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 

Notwithstanding the foregoing, the Collateral does not include: 

(i) more than 65% of the total combined voting power of all classes of stock entitled to vote the shares of capital stock
(the “Shares”) of any Subsidiary of Borrower not incorporated or organized under the laws of one of the States or jurisdictions of the United States (in the event that Borrower demonstrates to Collateral Agent’s reasonable
satisfaction that a pledge of more than sixty five percent (65%) of the Shares creates a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code); 

(ii) equipment (and any accessions, attachments, replacements or improvements thereon) that is subject to a Lien that is
a Permitted Lien, provided, that upon the release of any such Lien, such equipment (and any accessions, attachments, replacements or improvements thereon) shall be deemed to be Collateral hereunder and shall be subject to the security interest
granted; or 
 (iii) any license listed on Annex I hereto (each, an “Inbound License”) if and to the
extent such Inbound License includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of a Borrower therein would be prohibited and would, in and of itself, cause or
result in a default thereunder enabling the licensor to enforce any remedy with respect thereto; provided that the foregoing exclusion shall not apply if (a) such prohibition has been waived or such other person has otherwise consented to the
creation hereunder of a security interest in such Inbound License or (b) such prohibition would be rendered ineffective pursuant to Section 9-408 of the New York Uniform Commercial Code; provided further that immediately upon the
ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and such Borrower shall be deemed to have granted on the date hereof a security interest in, all its rights, title and interests in and to such Inbound
License as if such provision had never been in effect. 

 ANNEX I 
 (Licenses for Which Consent/Waiver Shall be Obtained – as of the Effective Date) 
 1. Exclusive License Agreement effective October 16, 2009 between University of Victoria Innovation and Development Corporation, The John Hopkins University and Protox Therapeutics Inc., as amended
by Exclusive License Amending Agreement made the 1st day of July, 2010 between University of Victoria Innovation and Development Corporation, The John Hopkins University and Protox Therapeutics Inc.; 

2. Exclusive License Agreement effective September 30, 2004 between University of Victoria Innovation and
Development Corporation, The John Hopkins University and Protox Therapeutics Inc., as amended by Amendment to Exclusive License Agreement dated December 8, 2004 (last party signed on January 10, 2005) between University of Victoria
Innovation and Development Corporation, The John Hopkins University and Protox Therapeutics Inc., as amended by Exclusive License Amending Agreement made the 1 st day of July, 2010 between University of Victoria Innovation and Development
Corporation, The John Hopkins University and Protox Therapeutics Inc.; 
 3. Patent License Agreement –
Exclusive, effective March 31, 2008, with respect to license L-087- 2008/0 between Protox Therapeutics Inc. and certain agencies of the United States Public Health Service within the Department of Health and Human Services; 

4. Patent License Agreement – Exclusive, effective July 18, 2006, with respect to license L-112- 2006/0 between
Protox Therapeutics Inc. and certain agencies of the United States Public Health Service within the Department of Health and Human Services, as amended by First Amendment To L-112-2006/0 effective July 24, 2008 between Protox Therapeutics Inc.
and certain agencies of the United States Public Health Service within the Department of Health and Human Services; 
 5. Patent License Agreement – Nonexclusive, effective July 24, 2008, with respect to license L-127- 2008/0 between Protox Therapeutics Inc. and certain agencies of the United States Public
Health Service within the Department of Health and Human Services; 
 in each case, as amended from time to time. 

 EXHIBIT B 
 Loan Payment/Advance Request Form 
 DISBURSEMENT LETTER

 The undersigned, being the duly appointed and acting Chief Operating Officer of PROTOX THERAPEUTICS INC., a
corporation amalgamated under the Business Corporations Act (British Columbia), with offices located at 1500 – 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3E8 (“Parent”), for itself and on behalf of
PROTOX THERAPEUTICS CORP., a Delaware corporation, with offices located at 1258 Prospect Street, La Jolla, California, 92037 (collectively with Parent, “Borrowers” and, each individually, a “Borrower”), does
hereby certify to OXFORD FINANCE LLC, (“Oxford” and “Lender”), as collateral agent (the “Collateral Agent”) in connection with that certain Loan and Security Agreement dated as of
July 15, 2011, by and between Borrowers, Collateral Agent and the Lenders from time to time party thereto (the “Loan Agreement”; with other capitalized terms used below having the meanings ascribed thereto in the Loan Agreement) that:

 1. The representations and warranties made by Borrowers in Section 5 of the Loan Agreement and in
the other Loan Documents are true and correct in all material respects as of the date hereof. 
 2. No event or
condition has occurred that would constitute an Event of Default under the Loan Agreement or any other Loan Document. 
 3. Each Borrower is in compliance with the covenants and requirements contained in Sections 4, 6 and 7 of the Loan Agreement. 

4. All conditions referred to in Section 3 of the Loan Agreement to the making of the Loan to be made on or
about the date hereof have been satisfied or waived by Collateral Agent. 
 5. No Material Adverse Change has
occurred. 
 6. The undersigned is a Responsible Officer. 

7. The proceeds of the Term Loans shall be disbursed as follows: 

 

					
	 Disbursement from Oxford:
	  			
	 Loan Amount
	  	$	15,000,000	  
	 Plus:
	  			
	 —Deposit Received
	  	$	150,000	  
		
	 Less:
	  			
	 —Lender’s Legal Fees
	  			
	 DLA Piper LLP (US)
	  	($	68,272.03	)* 
	 Aird & Berlis LLP
	  	($	29,186.42	)* 
	 — Facility Fee
	  	($	150,000	) 
		
	 Net Proceeds of Term Loan due from Oxford:
	  	$	14,902,541.55	  

  

	*	 Legal fees and costs are through the Effective Date. Post-closing legal fees and costs, payable after the Effective Date, to be invoiced and paid
post-closing. 

 8. The aggregate net proceeds of each Term Loan shall be transferred to
Parent’s account as follows: 
  

			
	DESTINATION BANK:	  	 Royal Bank of Canada

		  	 Toronto, Ontario, Canada

		  	 SWIFT CODE: ROYCCAT2

		
	BANK ADDRESS:	  	 Main Branch - Royal Centre, 1025 West

		  	 Georgia Street, Vancouver, BC V6E 3N9

		
	INTERMEDIARY BANK:	  	 JP Morgan Chase Bank

		  	 New York, NY

		  	 ABA # 021000021

		  	 SWIFT CODE: CHAS US 33

		
	BENEFICIARY ACCOUNT NAME:	  	 Protox Therapeutics Inc.

		  	 # 1500 – 885 W. Georgia St.

		  	 Vancouver, B.C. V6E 3N9

		
	BENEFICIARY ACCOUNT #:	  	 000104001145

 [Balance of Page Intentionally Left Blank] 

			
	 Dated as of the date first set forth above.

	
	 PARENT (for itself and on behalf of PROTOX

	 THERAPEUTICS CORP.):

	
	PROTOX THERAPEUTICS INC.
		
	 By
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	AS COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC
		
	 By
	 	  

	 Name:
	 	  

	 Title:
	 	  

 [Signature Page to Loan Payment/Advance Request Form; Disbursement Letter]

 EXHIBIT C -COMPLIANCE CERTIFICATE 

 

					
	TO:	  	Oxford Finance LLC, as Collateral Agent and Lender	  	
			
	FROM:	  	PROTOX THERAPEUTICS INC., for itself and on behalf of PROTOX THERAPEUTICS CORP.	  	

 The undersigned authorized officer of PROTOX THERAPEUTICS INC. (“Parent”), for itself and on
behalf of PROTOX THERAPEUTICS CORP. (each, a “Borrower” and collectively, “Borrowers”) hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement among Borrowers, Collateral Agent, and
the Lenders dated July 15, 2011 (the “Agreement”), 
 (i) Each Borrower is in complete compliance for the period
ending                      with all required covenants in the Agreement except as noted below; 

(ii) There are no Events of Default, except as noted below; 
 (iii) Except as noted below, all representations and warranties of each Borrower stated in the Loan Documents are true and correct in all material respects on this date except as noted below; provided,
however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties
expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date. 
 (iv)
Each Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and each Borrower has timely paid all foreign, federal, state, provincial and local taxes, assessments, deposits and contributions owed by such
Borrower except as otherwise permitted pursuant to the terms of Section 5.8 of the Agreement; 
 (v) No Liens have been
levied or claims made against any Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which such Borrower has not previously provided written notification to Collateral Agent 

Attached are the required documents, if any, supporting our certification(s). The undersigned on behalf of Borrowers further certifies
that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in
the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements. Capitalized terms used but not otherwise defined herein shall have the meanings given them in
the Agreement. 
 Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under
“Complies” column. 
  

																	
	 	  	 Reporting Covenant
	  	 Requirement
	  	Complies	 
	1)	  	Financial statements	  	Monthly within 30 days	  	 	Yes	  	  	 	No	  	  	 	N/A	  
						
	2)	  	Annual (CPA or Chartered Accountant Audited) financial statements	  	Within 120 days after Fiscal Year End	  	 	Yes	  	  	 	No	  	  	 	N/A	  
						
	3)	  	Annual Financial Projections/Budget (prepared on a monthly	  	Annually (w/n 30 days of FYE) and when revised	  	 	Yes	  	  	 	No	  	  	 	N/A	  

																			
	 	  	basis)	  	 	  	 	  	 	 	  	 	 	  	 	 
							
	4)	  	A/R & A/P agings	  	If applicable	  		  	 	Yes	  	  	 	No	  	  	 	N/A	  
							
	5)	  	Filings under applicable Canadian and/or securities laws	  	Within 5 days of filing	  		  	 	Yes	  	  	 	No	  	  	 	N/A	  
							
	6)	  	8-K, 10-K and 10-Q Filings	  	 If applicable; within 5
 days
of filing
	  		  	 	Yes	  	  	 	No	  	  	 	N/A	  
							
	7)	  	Compliance Certificate	  	Monthly within 30 days	  		  	 	Yes	  	  	 	No	  	  	 	N/A	  
							
	8)	  	IP Report	  	when required	  		  	 	Yes	  	  	 	No	  	  	 	N/A	  
							
	9)	  	Total amount of Parent’s cash and cash equivalents at the last day of the measurement period	  		  	 $            
	  				  				  			
							
	10)	  	Total amount of Protox US’s cash and cash equivalents at the last day of the measurement period	  		  	 $            
	  				  				  			
			
		  	Deposit and Securities Accounts	  	(Please list all accounts; attach separate sheet if additional space needed)	  
					
	 	  	 Bank
	  	 Account Number
	  	New Account	 	  	Acct Control
Agmt in 
place?	 
	1)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
							
	2)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
							
	3)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
							
	4)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
							
	5)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
							
	6)	  		  		  	Yes	  	 	No	  	  	 	Yes	  	  	 	No	  
						
		  	Financial Covenant	  	Requirement	  	Actual	  				  	 	Compliance	  
							
		  	 New Equity
	  	 1) $7,500,000 Cdn by
 December
31, 2011
	  	
$              
by            

	  				  	 	Yes	  	  	 	No	  
		  		  	 2) $7,500,000 Cdn by
 March 31,
2012
	  	
$              
by            

	  				  	 	Yes	  	  	 	No	  
							
		  	Other Matters	  		  		  				  				  			
					
		  	 Have there been any changes in management since the last Compliance Certificate?
	  				  	 	Yes	  	  	 	No	  

																					
		  	Have there been any transfers/sales/disposals/retirement of Collateral or Borrower’s Intellectual Property prohibited by the Agreement?	  	 	Yes	  	 	 	No	  
				
		  	Have there been any new or pending claims or causes of action against Borrower that involve more than $100,000?	  	 	Yes	  	 	 	No	  
									
		  	Exceptions	  		 		  		  		 		  				 			
			
		  		  	   
	    

		  	Please explain any

exceptions with respect to

the certification above: (If
 no
exceptions exist, state
 “No exceptions.” Attach
 separate sheet if additional
 space needed.)
	  
	  	  	   
	    

	  	  	   
	    

	  	  	   
	    

					
		  		  		 	  
	  	LENDERS USE
 ONLY
	  
   

		  	PROTOX
 THERAPEUTICS INC.
	  		 	     DATE
	  		 		  				 			
									
		  	By:	  		 		  		  	Received by:	 	            	  	 	Verified by:	  	 	 	            	  
									
		  	Name:	  		 		  		  		 		  				 			
		  	Title:	  		 		  		  	Date:	 	            	  	 	Date:	  	 	 	            	  
									
		  		  		 		  		  	Compliance Status	 		  	 	Yes	  	 	 	No	  

 EXHIBIT D 

 SECURED PROMISSORY NOTE 

(NOTE 1) 
  

			
	$10,000,000	  	Dated: July 15, 2011

 FOR VALUE RECEIVED, the undersigned, PROTOX THERAPEUTICS INC., a corporation
amalgamated under the Business Corporations Act (British Columbia) with offices located at 1500 – 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3E8 (“Parent”) and PROTOX THERAPEUTICS CORP., a
Delaware corporation, with offices located at 1258 Prospect Street, La Jolla, California, 92037 (collectively with Parent, “Borrowers” and, each individually, a “Borrower”), each HEREBY JOINTLY AND SEVERALLY PROMISE
TO PAY to the order of OXFORD FINANCE LLC (“Lender”) the principal amount of TEN MILLION DOLLARS ($10,000,000) or such lesser amount as shall equal the outstanding principal balance of the Term Loan made to Borrowers by
Lender, plus interest on the aggregate unpaid principal amount of the Term Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated as of July 15, 2011 by and among Borrowers, Oxford Finance LLC, as
Collateral Agent and as a Lender, and the Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If not sooner paid, the entire outstanding principal
amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan
Agreement. 
 Borrowers agree, jointly and severally, to pay any initial partial monthly interest payment from the date the Term
Loan is made to Borrowers under this Secured Promissory Note (this “Note”) to the first Payment Date (“Interim Interest”) on the first Payment Date. 
 Principal, interest and all other amounts due with respect to the Term Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Note. The
principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note.

 The Loan Agreement, among other things, (a) provides for the making of a secured Term Loan by Lender to Borrowers, and
(b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be
prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 
 This Note and the
obligation of Borrowers to repay the unpaid principal amount of the Term Loan, interest on the Term Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement. 

Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution,
delivery, performance and enforcement of this Note are hereby waived. 
 Borrowers shall pay all reasonable fees and expenses,
including, without limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrowers’ obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

Note Register; Ownership of Note. The ownership of an interest in this Note shall be registered on a record of ownership
maintained by Lender or its agent. Notwithstanding anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the
transferee is identified as the owner of an interest in the obligation, and subject to certain restrictions set forth in the Loan Agreement. Borrowers shall be entitled to treat the registered holder of this Note (as recorded on such record of
ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Note on the part of any other person or entity. 

 IN WITNESS WHEREOF, Borrowers have caused this Note to be duly executed by
one of its officers thereunto duly authorized on the date hereof. 
  

									
	BORROWERS:	 		 		 	
			
	PROTOX THERAPEUTICS INC.	 		 	PROTOX THERAPEUTICS CORP.
					
	 By
	 	  
	 		 	 By
	 	  

	 Name:
	 	  
	 		 	 Name:
	 	  

	 Title:
	 	  
	 		 	 Title:
	 	  

 LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL 

 

									
	 Date
	  	Principal
Amount	  	Interest
Rate	  	Scheduled
Payment
Amount	  	Notation
By
		  		  		  		  	
		  		  		  		  	

 SECURED PROMISSORY NOTE 

(NOTE 2) 
  

			
	$5,000,000	  	Dated: July 15, 2011

 FOR VALUE RECEIVED, the undersigned, PROTOX THERAPEUTICS INC., a corporation
amalgamated under the Business Corporations Act (British Columbia) with offices located at 1500 – 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3E8 (“Parent”) and PROTOX THERAPEUTICS CORP., a
Delaware corporation, with offices located at 1258 Prospect Street, La Jolla, California, 92037 (collectively with Parent, “Borrowers” and, each individually, a “Borrower”), each HEREBY JOINTLY AND SEVERALLY PROMISE
TO PAY to the order of OXFORD FINANCE LLC (“Lender”) the principal amount of FIVE MILLION DOLLARS ($5,000,000) or such lesser amount as shall equal the outstanding principal balance of the Term Loan made to Borrowers by
Lender, plus interest on the aggregate unpaid principal amount of the Term Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated as of July 15, 2011 by and among Borrowers, Oxford Finance LLC, as
Collateral Agent and as a Lender, and the Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If not sooner paid, the entire outstanding principal
amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan
Agreement. 
 Borrowers agree, jointly and severally, to pay any initial partial monthly interest payment from the date the Term
Loan is made to Borrowers under this Secured Promissory Note (this “Note”) to the first Payment Date (“Interim Interest”) on the first Payment Date. 
 Principal, interest and all other amounts due with respect to the Term Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Note. The
principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note.

 The Loan Agreement, among other things, (a) provides for the making of a secured Term Loan by Lender to Borrowers, and
(b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be
prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement. 
 This Note and the
obligation of Borrowers to repay the unpaid principal amount of the Term Loan, interest on the Term Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement. 

Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution,
delivery, performance and enforcement of this Note are hereby waived. 
 Borrowers shall pay all reasonable fees and expenses,
including, without limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrowers’ obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York. 

Note Register; Ownership of Note. The ownership of an interest in this Note shall be registered on a record of ownership
maintained by Lender or its agent. Notwithstanding anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the
transferee is identified as the owner of an interest in the obligation, and subject to certain restrictions set forth in the Loan Agreement. Borrowers shall be entitled to treat the registered holder of this Note (as recorded on such record of
ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Note on the part of any other person or entity. 

 IN WITNESS WHEREOF, Borrowers have caused this Note to be duly executed by
one of its officers thereunto duly authorized on the date hereof. 
  

									
	BORROWERS:	 		 		 	
			
	PROTOX THERAPEUTICS INC.	 		 	PROTOX THERAPEUTICS CORP.
					
	 By
	 	  
	 		 	 By
	 	  

	 Name:
	 	  
	 		 	 Name:
	 	  

	 Title:
	 	  
	 		 	 Title:
	 	  

 LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL 

 

									
	 Date
	  	Principal
Amount	  	Interest
Rate	  	Scheduled
Payment
Amount	  	Notation
ByIntellectual Property Security Agreement of Sophiris Bio Inc

 Exhibit 10.20 
 INTELLECTUAL PROPERTY SECURITY AGREEMENT 
 This Intellectual Property
Security Agreement is entered into as of the Effective Date by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the “Lenders”) described in the Loan Agreement (in such capacity, the “Collateral Agent”) and
PROTOX THERAPEUTICS INC. (“Grantor”). 
 RECITALS 

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”)
in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, the Lenders, Protox Therapeutics Corp. and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from
time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to
Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement. 

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security
interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral. 
 NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its
obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows: 
 AGREEMENT

 To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of
the Lenders, a continuing security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto),
and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights
corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof. 
 This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral
Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as
a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be
in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the
other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies. 

New York law governs this Intellectual Property Security Agreement without regard to principles of conflicts of law. This Intellectual
Property Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one agreement. 

[Balance of Page Intentionally Left Blank] 

  
 Page 1 of 8

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed by its officers thereunto duly authorized as of the first date written above. 
  

							
	GRANTOR:	 		 		 	
			
	Address of Grantor:	 		 	PROTOX THERAPEUTICS, INC.
				
	1500 – 885 West Georgia Street,	 		 	By:	 	 /s/ A. Hulme

	Vancouver, British Columbia, Canada, V6C 3E8	 		 		 	
	Attn: Chief Financial Officer	 		 	Title:	 	 Chief Operating Officer

			
		 		 	COLLATERAL AGENT:
			
	Address of Lender:	 		 	OXFORD FINANCE LLC
				
	133 North Fairfax Street	 		 	By:	 	  

	Alexandria, Virginia 22314	 		 		 	
	Attn: General Counsel	 		 	Title:	 	  

 [Signature Page to Intellectual Property Security Agreement] 

  
 Page 2 of 8

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed by its officers thereunto duly authorized as of the first date written above. 
  

							
	GRANTOR:	 		 		 	
			
	Address of Grantor:	 		 	PROTOX THERAPEUTICS, INC.
				
	1500 - 885 West Georgia Street,	 		 	By:	 	  

	Vancouver, British Columbia, Canada, V6C 3E8	 		 		 	
	Attn: Chief Financial Officer	 		 	Title:	 	  

			
		 		 	COLLATERAL AGENT:
			
	Address of Lender:	 		 	OXFORD FINANCE LLC
				
	133 North Fairfax Street	 		 	By:	 	 /s/ TAZ

	Alexandria, Virginia 22314	 		 		 	
	Attn: General Counsel	 		 	Title:	 	 COO

 [Signature Page to Intellectual Property Security Agreement] 

  
 Page 3 of 8

 EXHIBIT A 
 Copyrights 
  

					
	 Description
	  	 Registration Number
	  	 Registration Date

			
	 None.
	  		  	

  
 Page 4 of 8

 EXHIBIT B 
 Patents 
  

							
	 Description
	  	 Patent/App. No.
	  	 File Date
	  	Country
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2002331720	  	8/23/02	  	Australia
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2,457,903	  	8/23/02	  	Canada
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2816622.1	  	8/23/02	  	China
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2768702.9	  	8/23/02	  	EPC
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	TBD (divisional)	  	8/23/02	  	EPC
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2003-523270	  	8/23/02	  	Japan
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	10/487,115	  	2/18/04	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	11/856,543	  	9/17/07	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	12/788,913	  	5/27/10	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2004/02319	  	8/23/02	  	South Africa
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	00379/KOLNP/04	  	8/23/02	  	India
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2389/KOLNP/2007	  	3/22/04	  	India
				
	Modified pore-forming protein toxins and use thereof	  	12/094,597	  	11/21/06	  	U.S.
				
	Modified pore-forming protein toxins and use thereof	  	2630559	  	11/21/06	  	Canada
				
	Modified pore-forming protein toxins and use thereof	  	6804758.8	  	11/21/06	  	EPC
				
	Modified pore-forming protein toxins and use thereof	  	11166965.1	  	5/20/11	  	EPC
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	  	2006257664	  	6/14/06	  	Australia
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	  	2,611,839	  	6/14/06	  	Canada

  
 Page 5 of 8

							
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	200680028473.6	 	6/14/06	 	China
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	6761050.1	 	6/14/06	 	EPC
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	188143	 	6/14/06	 	Israel
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	2008-516088	 	6/14/06	 	Japan
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	564954	 	6/14/06	 	New Zealand
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	200718733-9	 	6/14/06	 	Singapore
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	11/921,964	 	12/10/07	 	U.S.
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	10-2008-7001038	 	6/14/06	 	Korea
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	2007/10813	 	6/14/06	 	South Africa
				
	Method for treating prostatitis utilizing modified pore-forming protein proaerolysin	 	PCT/CA2009/001837	 	12/15/09	 	PCT
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	08/225,224	 	6/03/97	 	U.S.
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	1995022857	 	11/5/98	 	Australia
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	2,187,283	 	9/23/08	 	Canada
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	95916319.7	 	1/29/03	 	EPC
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	08/722,258	 	12/10/07	 	U.S.
				
	Convection enhanced drug delivery	 	616,785	 	2/24/98	 	U.S.
				
	Method for convection enhanced delivery of therapeutic agents	 	2003299140	 	9/24/03	 	Australia
				
	Method for convection enhanced delivery of therapeutic agents	 	2,499,573	 	9/24/03	 	Canada
				
	Method for convection enhanced delivery of therapeutic agents	 	3756863.1	 	9/24/03	 	EPC

  
 Page 6 of 8

							
	Method for convection enhanced delivery of therapeutic agents	 	10/528,310	 	9/24/03	 	U.S.
				
	Treating cancer stem cells using targeted cargo proteins	 	PCT/CA2009/001323	 	9/21/09	 	PCT
				
	Treating cancer stem cells using targeted cargo proteins	 	13/119,426	 	3/16/11	 	U.S.
				
	Targeted cargo protein combination therapy	 	12/579,281	 	10/14/09	 	U.S.
				
	Use of human serum albumin to decrease antigenicity of therapeutic proteins	 	61/406,052	 	10/22/10	 	U.S. Provisional
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	2,622,504	 	9/8/06	 	Canada
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	6851440.5	 	9/8/06	 	EPC
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	2008-536580	 	9/8/06	 	Japan
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	11/91,692	 	9/8/06	 	U.S.
				
	Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis	 		 	5/15/04	 	U.S.
				
	Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis	 	12/147,924	 	6/27/08	 	U.S. Divisional

  
 Page 7 of 8

 EXHIBIT C 
 Trademarks 
  

					
	 Description
	  	 Serial/Registration No.
	  	 File Date

			
	None.	  		  	

  
 Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]